Official Title of the study: Vectors Post Market: A study to assess pain relief using spinal cord 
stimulation with high dose stimulation parameters  
NCT number: [STUDY_ID_REMOVED] 
Date of document: 08MAY2018  
Document Type: Study Protocol  
 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 1of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateClinical Investigation Plan
Clinical Investigation Plan Title Vectors Post Market: A study to assess pain relief 
using spinal cord stimulation (SCS) with high dose 
(HD)stimulation parameters
Clinical Investigation Plan Identifier MDT1 7053
Product Name Medtronic RestoreSensor® SureSc an® MRI and 
IntellisTMAdaptiveStim® Neurostimulation System
Global Sponsor Medtronic, Inc
Medtronic Neuromodulation
7000 Central Ave NE
Minneapolis, MN, 55432 
U.S.A.
+1-763-514-4000
Document Version V4.008 MAY 2018
Confidentiality Statement
The information contained inthis document isconfidential and theproprietary property of
Medtronic. Any distribution, copying, ordisclosure without theprior written authorization of
Medtronic isstrictly prohibited. Persons towhom theinformation isdisclosed must know that itis
confidential and that itmay notbefurther disclosed bythem.

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 2of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template1. Investigator Statement
Participating investigators will be provided with a separate Investigator Agreement to document their 
obligations and commitment with respect to study conduct .
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 3of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateTable of Contents 
1. Investigator Statement ................................ ................................ ................................ ......2
Table of Contents ................................ ................................ ................................ ...................... 3
Table of Tables ................................ ................................ ................................ .......................... 8
Table of Figures ................................ ................................ ................................ ......................... 8
2. Glossary ................................ ................................ ................................ .............................. 9
3. Synopsis ................................ ................................ ................................ ........................... 10
4. Introduction ................................ ................................ ................................ ..................... 15
4.1.Background ................................ ................................ ................................ ........................... 15
4.2.Purpose ................................ ................................ ................................ ................................ .17
4.3.Regulatory Study Classification ................................ ................................ ............................... 17
5. Objectives and Endpoints ................................ ................................ ................................ .18
5.1.Objectives ................................ ................................ ................................ ............................. 18
5.1.1. Primary Objective(s) ................................ ................................ ................................ .............. 18
5.1.2. Safety Assessment ................................ ................................ ................................ ................. 18
5.1.3. Secondary Objective(s) ................................ ................................ ................................ .......... 18
5.1.4. Additional Measures ................................ ................................ ................................ ............. 18
6. Study Design ................................ ................................ ................................ .................... 19
6.1.Duration ................................ ................................ ................................ ................................ 22
6.2.Rationale ................................ ................................ ................................ ............................... 22
7. Product Des cription ................................ ................................ ................................ .......... 22
7.1.General ................................ ................................ ................................ ................................ .22
7.2.Manufacturer ................................ ................................ ................................ ......................... 23
7.3.Packaging ................................ ................................ ................................ .............................. 23
7.4.Intended Population ................................ ................................ ................................ ............... 23
7.4.1. Intended Populations: United States ................................ ................................ .................... 23
7.5.Product Use ................................ ................................ ................................ ........................... 24
7.6.Product Training Requirements ................................ ................................ ............................... 24
7.7.Product Accountability ................................ ................................ ................................ ............ 24
7.8.Product Return ................................ ................................ ................................ ...................... 24
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 4of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template8. Selection of Subjects ................................ ................................ ................................ ........ 24
8.1.Study Population ................................ ................................ ................................ .................... 24
8.2.Subject Enrollment ................................ ................................ ................................ ................. 24
8.3.Inclusion Criteria ................................ ................................ ................................ .................... 25
8.4.Exclusion Criteria ................................ ................................ ................................ ................... 25
9. Study Procedures ................................ ................................ ................................ ............. 26
9.1.Summary of Visits ................................ ................................ ................................ .................. 26
9.2.Baseline Visit ................................ ................................ ................................ ......................... 27
9.3.Device Trial ( ≤ 14 days post -Baseline) ................................ ................................ .................... 28
9.4.Implant Visit ( ≤ 30 days from trial lead explant) ................................ ................................ ......33
9.5.Device Activation Visit (Day 0; 9 –16 days after i mplant) ................................ ......................... 34
9.6.2-Week, 4 -Week, 6 -Week and 3 -, 6-, and 12 -Month Clinic Visits ................................ ............... 36
9.7.Telephone Calls (1, 3, 5, 7, 8, 9, 10 and 11 weeks post -device activation; Monthly Telephone Calls 
at 3.5, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5, 10.5, 11.5 Months post -3-Month Visit) ................................ ......... 38
9.8.Unscheduled Visits: ................................ ................................ ................................ ................ 39
9.9.System Modifications: ................................ ................................ ................................ ............ 39
9.10. Study Exit ................................ ................................ ................................ ........................ 39
9.11. Schedule of Events ................................ ................................ ................................ ........... 40
9.12. Subject Screening ................................ ................................ ................................ ............ 41
9.13. Prior and Concomitant Medications ................................ ................................ .................... 41
9.14. Subject Consent ................................ ................................ ................................ ............... 42
9.15. Assessment of Efficacy ................................ ................................ ................................ .....43
9.15.1. Single -day Visual Analog Scale (VAS) ................................ ................................ ................. 43
9.15.2. Percent Improvement in Overall Pain Assessment ................................ ........................... 44
9.15.3. Patient Global Impression of Change (PGIC) ................................ ................................ .....44
9.15.4. Pain Relief Assessment ................................ ................................ ................................ ......44
9.15.5. Recharging Questionnaire ................................ ................................ ................................ .44
9.15.6. Paresthesia Assessment ................................ ................................ ................................ ....44
9.15.7. Subject Satisfaction Assessment (SSA) ................................ ................................ .............. 45
9.15.8. European Quality of Life -Five Dimensions ................................ ................................ ......... 45
9.15.9. ODI................................ ................................ ................................ ................................ .....45
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 5of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template9.15.10. Activity Goal ................................ ................................ ................................ ....................... 45
9.15.1 1. Back Pain/Surgical History and Demographics ................................ ................................ ..45
9.16. Assessment of Safety ................................ ................................ ................................ .......45
9.17. Recording Data ................................ ................................ ................................ ................ 45
9.17.1. Programming Data ................................ ................................ ................................ ............. 46
9.17 .2. Fluoroscopy/x -ray imaging ................................ ................................ ................................ 46
9.18. Deviation Handling ................................ ................................ ................................ ........... 47
9.19. Subject Withdrawal or Discontinuation ................................ ................................ ............... 48
9.20. Pregnancy ................................ ................................ ................................ ........................ 49
10. Risks and Benefits ................................ ................................ ................................ ............ 49
10.1. Potential Risks ................................ ................................ ................................ .................. 49
10.1.1 . Risks of Surgery ................................ ................................ ................................ .................. 50
10.1.2. Spinal Cord Stimulation Risks ................................ ................................ ............................ 50
10.1.3. System Revision Risk ................................ ................................ ................................ .......... 51
10.1.4. Risks Associated with the Recharge System ................................ ................................ ......51
10.1.5. Pregnancy Risks ................................ ................................ ................................ ................. 53
10.1.6. Radiographic Imaging ................................ ................................ ................................ ........ 53
10.2. Study Risk Control Measures ................................ ................................ ............................. 53
10.3. Potential Benefits ................................ ................................ ................................ ............. 53
10.4. Risk-Benefit Rationale ................................ ................................ ................................ .......54
11. Adverse Events and Device Deficiencies ................................ ................................ .......... 55
11.1. Definitions/Classifications ................................ ................................ ................................ ..55
11.2. Foreseeable Adverse Events and Anticipated Adverse Device Effects ................................ ...56
11.3. Recording of Adverse Events ................................ ................................ ............................. 57
11.4. Recording of Device Deficiencies ................................ ................................ ....................... 57
11.5. Adverse Event and Device Deficiency Reporting Requirements ................................ ............ 58
11.6. Non-Reportable Events ................................ ................................ ................................ .....58
11.7. Emergency Contact Details ................................ ................................ ............................... 59
11.8. Deaths ................................ ................................ ................................ ............................. 59
12. Data Review Committees ................................ ................................ ................................ .60
13. Statistical Design and Methods ................................ ................................ ........................ 60
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 6of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template13.1. General Statistical Considerations ................................ ................................ ...................... 60
13.1.1. Analysis populations ................................ ................................ ................................ .......... 60
13.1.2. Handling of missing data ................................ ................................ ................................ ...61
13.1.3. Interim efficacy analyses ................................ ................................ ................................ ...61
13.1.4. Center pooling ................................ ................................ ................................ ................... 62
13.1.5. Multiple testing adjustment ................................ ................................ .............................. 62
13.1.6. Reports ................................ ................................ ................................ .............................. 62
13.2. Demographics ................................ ................................ ................................ .................. 62
13.3. Primary Objective ................................ ................................ ................................ ............. 62
13.3.1. Primary objective ................................ ................................ ................................ ............... 62
13.3.2. Hypothesis ................................ ................................ ................................ ......................... 63
13.3.3. Endpoint definition ................................ ................................ ................................ ............ 63
13.3.4. Study sample size justification ................................ ................................ ........................... 63
13.3.5. Analysis methods ................................ ................................ ................................ ............... 63
13.3.6. Handling of missing data ................................ ................................ ................................ ...63
13.3.7. Sensitivity analyses ................................ ................................ ................................ ............ 63
13.4. Secondary Objectives ................................ ................................ ................................ .......64
13.4.1. Secondary objective 1: Overall pain responder rate ................................ ......................... 64
13.4.2. Secondary objective 2: Low back pain responder rate ................................ ..................... 65
13.4.3. Secondary objective 3: Leg p ain responder rate ................................ ............................... 66
13.4.4. Sensitivity analyses for the secondary objectives ................................ ............................. 67
13.5. Additional Measures ................................ ................................ ................................ ......... 67
13.6. Safety Assessment ................................ ................................ ................................ ........... 68
14. Ethics ................................ ................................ ................................ ................................ 69
14.1. Statements of Compliance ................................ ................................ ................................ 69
15. Study Administration ................................ ................................ ................................ ....... 69
15.1. Monitoring ................................ ................................ ................................ ....................... 69
15.2. Medtronic Representative Role ................................ ................................ .......................... 70
15.3. Data Management ................................ ................................ ................................ ............ 71
15.4. Direct Access to Source Data/Documents ................................ ................................ ........... 72
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 7of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template15.5. Confidentiality ................................ ................................ ................................ .................. 72
15.6. Liability ................................ ................................ ................................ ............................ 73
15.7. CIP Amendments ................................ ................................ ................................ ............. 73
15.8. Record Retention ................................ ................................ ................................ ............. 73
15.8.1. Investigator Records ................................ ................................ ................................ .......... 73
15.8.2. Investigator Reports ................................ ................................ ................................ .......... 74
15.9. Publication and Use Information ................................ ................................ ........................ 74
15.10. Suspension or Early Termination ................................ ................................ ....................... 75
15.10.1. Study -wide termination or suspension ................................ ................................ ............. 75
15.10.2. Investigator/center termination or suspension ................................ ................................ 75
16. References ................................ ................................ ................................ ....................... 77
17. Appendices ................................ ................................ ................................ ....................... 78
17.1. Appendix A Additional Information for Sites ................................ ................................ .......78
17.2. Appendix B: Institutional Review Boards ................................ ................................ ............ 78
17.3. Appendix C: Participating Investigators and Institutions ................................ ...................... 78
18. Version History ................................ ................................ ................................ ................. 78
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 8of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateTable of Tables
Table 1 SCS Dose ................................ ................................ ................................ ................................ ......... 16
Table 2. Protocol Visit Windows ................................ ................................ ................................ ................. 26
Table 3. Recommended Permanent Implant Programming Algorithm ................................ ...................... 36
Table 4: Schedule of Events ................................ ................................ ................................ ........................ 40
Table 5. Data collection requirements for subject withdrawal ................................ ................................ ..49
Table 6: Expected Surgical Adverse Events and Durations ................................ ................................ ......... 59
Table 7. 95% Confidence Interval (CI) for Responder Rate = 50% ................................ .............................. 65
Table 8. 95% Confidence Interval (CI) for Responder Rate = 50% ................................ .............................. 66
Table 9. 95% Confidence Interv al (CI) for Responder Rate = 50% ................................ .............................. 67
Table of Figures
Figure 1. Vectors study visit flowchart ................................ ................................ ................................ ........ 21
Figure 2. Recharger and AC power supply ................................ ................................ ................................ ..52
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 9of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template2. Glossary
Abbreviation Term
ADE Adverse Device Effect
AE Adverse Event
AEAC Adverse Events Advisory Committee
AGA Activity Goal Assessment
AP Anteroposterior Position
ASADE Anticipated Serious Adverse Device Effect 
CIP Clinical Investigation Plan
CRF Case Report Form
CRPS Complex Regional Pain Syndrome
DD Device Deficiency
DDD Degenerative Disk Disease 
DMC Data Monitoring Committee
EC Ethics Committee
eCRF Electronic Case Report Form
ENS External Neurostimulator
EQ-5D-5L EuroQol Five Dimensions Questionnaire
FBS Failed Back Syndrome
HD High Dose
IC Informed Consent
ICF Informed Consent Form
ICH International Conference on Harmonization
INS Implantable Neurostimulator
IRB Institutional Review Board
LTFU Lost to Follow -up
MLTC Multi -Lead Trialing Cable 
NPU Neuro Programmer Upload
ODI Oswestry Disability Index
OUS Outside US
PGIC Patient Global Impr ession of Change
PMA Pre-Market Application
RCT Randomized Controlled Trial
RDC Remote Data Capture
RSD Reflex Sympathetic Dystrophy 
SADE Serious Adverse Device Effect 
SAE Serious Adverse Event 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 10of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAbbreviation Term
SAP Statistical Analysis Plan
SCS Spinal Cord Stimulation 
SSA Subject Satisfaction Assessment
US United States
USADE Unanticipated Serious Adverse Device Effect 
VAS Visual Analog Scale
Terms Definitions
High Dose (HD) 
StimulationFor the purposes of the Vectors Post Market study, HD stimulation is 
stimulation delivered at a pulse width of 90 –200 µsec and 1000 Hz at a
comfortable amplitude or intensity
Overall pain The combination of low back and leg pain. For the purposes of this study, the 
HD stimulation responder rate, using the VAS for overall pain, will be compar ed 
against the performance goal
Painful Paresthesia Uncomfortable or unexpected stimulation (e.g. jolting or shocking sensation 
experienced by the patient) due to excessive SCS therapy
Paresthesia Tingling sensation typically generated by SCS therapy 
Paresthesia 
MappingTest stimulation used to determine if area of stimulation overlaps with a 
subject’s areas of pain
Perception 
thresholdThe stimulation intensity at which the subject first perceives paresthesia
Visual Analog Scale For the purposes of the Vectors Post Market study ,the visual analog scale (VAS) 
will always be a single day score.
3. Synopsis
Title Vectors Post Market : A study to assess pain relief using spinal cord stimulation 
(SCS) with high dose ( HD)stimulation parameter s
Clinical Study 
TypePost -Market study
Product Name Medtronic RestoreSensor® SureScan® MRI and IntellisTMAdaptiveStim® 
Neurostimulation System
Global Sponsor Medtronic , Inc.
Medtronic Neuromodulation
7000 Central Ave NE
Minneapolis, MN, 55432 
U.S.A.
+1-763-514-4000
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 11of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateIndication U nder 
Investigation Spinal cord stimulation as an aid in the management of chronic, intractable pain 
of the trunk and/or limbs .
Investigation 
PurposeThe purpose of this study is to evaluate the efficacy of spinal cord stimulation 
(SCS) therapy using HD stimulation parameter s while targeting a specific 
anatomical location.
Primary 
Objective(s)To demonstrate a significant improvement in overall (low back and leg) pain 
intensity using HD stimulation starting at 90 -200 µsecand 1000 Hz with lead 
placement spanning the T9/ T10 disc space , as measured by the Visual Analog 
Scale (VAS), from Baseline to the 3 -Month Visit .
Safety 
AssessmentThis study will characterize all device -, therapy -, or procedure -related adverse 
events and device deficiencies from enrollment to the stud y exit. 
Secondary 
Objective(s)1.To characterize the overall (low back and leg) pain efficacy responder rate, as 
measured by the VAS, from Baseline to the 3 -Month Visit, with a confidence 
interval within ± 10%
2.To characterize the low back pain efficacy res ponder rate, as measured by the 
VAS, from Baseline to the 3 -Month Visit, with a confidence interval within ±
10%
3.To characterize the leg pain efficacy responder rate, as measured by the VAS, 
from Baseline to the 3 -Month Visit, with a confidence interval wi thin ±10%.
Additional 
Measures 
 
 
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 12of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
Study Design This is a global, prospective, single -arm, multi -center, non-randomized study 
evaluating the efficacy of SCS therapy for pain relief using HD stimulation 
parameters while targeting a specific anatomical location .  The study will be 
conducted at up to 30centers in the globally .
Sample Size Up to 215 subjects will be enrolled globally .
Inclusion/
Exclusion 
CriteriaInclusion Criteria
1.Willing and able to provide a signed and dated informed consent 
2.At least 18 years old at the time of enrollment
3.Candidate per labeling for an SCS system (trial and implant) as an aid in the 
management of chronic, intractable pain of the trunk and limbs ( low back and 
leg pain)
4.Baseline VAS is ≥ 50 mm for low back pain
5.Baseline VAS is ≥ 50 mm for legpain
6.ODI score of 21to 80 out of 100
7.On stable (no change in dose, route, or fre quency )pain medications 
(prescribed and over -the- counter) being used for back and leg pain, as 
determined by the investigator, for at least 28 days prior to enrolling in the 
study
8.Willing and able to attend visits and comply with the study protocol
9.Willin g and able to not increase their pain medications (prescribed and over -
the-counter) being used specifically for back orleg pain through the 3 -Month 
Visit
Additional Inclusion Criteri on (evaluated at Device Trial -Implant)
1.After paresthesia mapping to confirm proper location at Device Trial , final 
lead placement spans the T9/ T10 disc space
2.After paresthesia mapping to confirm proper location at permanent implant , 
final lead placement spans the T9/ T10 disc space
Exclusion Criteria

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 13of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template1.Previously t rialed or i mplante d with spinal cord stimulator, peripheral nerve 
stimulat or,or an implantable intrathecal drug delivery system
2.Expected to be inaccessible for follow -up
3.Subject is currently participating, or plans to participate, in another 
investigational study un less written approval is provided by the Medtronic 
study team
4.Current diagnosis of moderate to seve re central lumbar spinal stenosis with 
neurogenic claudication, as determined by the investigator
5.Major psychiatric comorbidity or other progressive diseases that may 
confound study results , as determined by the investigator
6.Serious drug -related behavioral issues (e.g. alcohol dependency, illegal 
substance abuse), as determined by the investigator
7.Pregnant o r planning on becoming pregnant (if female and sexually active, 
subject must be using a reliable form of birth control, be surgically sterile, or 
be at least 2 years post -menopausal )
8.Unable to achieve supine position
Study 
Procedures and 
AssessmentsSpecific data and procedure requirements per visit are summarized in Table 4.  
Study Visits
Baseline Visit
Device Trial Day 0 –Lead Placement and initial programming
Device Trial Day 2
Device Trial Day 4 (if necessary)
Device Trial Day 6 (if necessary)
Implant
Device Activation Visit
2-Week Visit
4-Week Visit
6-Week Visit
3-Month Visit
6-Month Visit
12-Month /Final Visit
Baseline Visit:
Subjects are considered enrolled at the time the study -specific informed 
consent /HIPAA form (or other data protection authorization as required by local 
regulations) is signed.  Subjects in compliance with inclusion/exclusion criteria will 
be eligible to participate.  A VAS score for overall ( low back and leg), back, and leg 
will be collected. Subjects that do not have a VAS ≥ 50 mm for low back pain and 
VAS ≥ 50 mm for leg pain will be exited from the study.   Subjects that meet the 
pain inclusion criteria will be asked about their back and leg pain/surgical history, 
be sched uled for a device trial ,and complete the required assessments (e.g.,EQ-
5D-5L,ODI, and activity goal ).  
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 14of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateDevice Trial :Day 0 (≤14 days post Baseline Visit)
At Day 0, s ubjects willbe implanted with two percutaneous leads per labeling . 
Subjects who have leads spanning the T9/T10 disc space will continue in the 
study.  In the recovery room, subjects who have electrodes over the T9/T10 disc
space will be programmed with 1 HD programming configuration . 
Device Trial Day 2 :(2 –4 days after Device Trial Day 0)
The effectiveness of the stimulation parameters programmed at Day 0 will be 
assessed for 2 days.  If a subject has ≥50% reduction in pain , they will have their 
trial leads explanted and proceed to implant.   If a subj ect does not have ≥50% 
pain relief, they will be reprogrammed to the second HD group and return for a 
Day 4 Visit.
Device Trial Day 4, if necessary: (2 –4 days after Day 2 Visit)
The effectiveness of the stimulation parameters programmed at Day 2 will b e 
assessed for 2 days.  If a subject has ≥50% reduction in pain , they will have their 
trial leads explanted and proceed to implant.   If a subject does not have ≥50% 
pain relief, they will be reprogrammed using any on -label parameters ( physician 
preferenc e)and return for a Day 6 Visit
Device Trial Day 6, if necessary : (2 –4 days after Day 4 Visit; no later than Day 
10) 
Subjects willreturn to the clinic a minimum of two days later to assess the 
effectiveness of the physician preference stimulation parameters programmed at 
Day 4 and have their trial leads explanted.  These subjects will then be exitedfrom 
the study.
Implant (≤ 30 days post end of device trial)
Subjects who were HD responders during the device trial and who met all 
eligibility criteria will be implanted with a RestoreSensor SureScan MRI or Intellis 
AdaptiveStim neurostimulat ionsystem . Subjects will be implanted with two 
compact percutaneous leads per labeling .Subjects who have leads spanning the 
T9/T10 disc space will continue in the study .The stimulator will be “OFF” when 
the subject leaves this visit.
Device Activation Visit (9 –16 days post implant) The Device Activation Visit will 
take place 9 –16days after implant, pending wound hea ling. The stimulator will 
be turned “ON” at this visit and the programming that was successful for the trial 
will be programmed for that subject .
Follow -upVisits ( 2 weeks, 4 weeks , 6 weeks ± 3 days and 3, 6, and 12Months ± 
15 days post Device Activation )
Visits will occur at weeks 2 ,4and 6 and months 3, 6 and 12 post device activation .  
EQ-5D-5L, ODI, PGIC, and SSA will be assessed at 3 -, 6-and 12 -Months. The VAS 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 15of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatewill be administered at all follow -up visits and scored by site personnel. The 
Paresthesi a Assessment and Recharging Questionnaire will be collected at the 3 -
and 12 -Month Visits.  The Activity Goal will be completed through the 3 -Month 
Visit . Data for the primary endpoint will be collected at the 3 -Month Visit .
Telephone Calls (Daily during Device Trial, Monthly post Device Activation )
Subjects will be called 1, 3, 5, 7, 8, 9, 10 and 1 1weeks post -device activation to 
assess their pain relief status and then monthly following the 3 -Month Visit .  If the 
subject reports inadequate pa in relief, they will come in for an unscheduled visit .
StatisticsOnly subjects who are implanted and have their devices activated will be included 
in the evaluation of the primary and secondary endpoints.  The study sample size 
is based on the desired pre cision for the characterization of the secondary 
objectives. A sample size of 100 subjects provides a 95% confidence interval 
within 9.6% of the responder rate estimate, if the observed responder rate is 50%. 
For the primary objective, a sample size of 100 subjects ensures over 99% power 
to test a significant change from 0 under the following assumptions: two-sided 
alpha = 0.05, assumed mean reduction = 20 with a standard deviation = 30. 
Globally up to 215 subjects will be enrolled to ensure at least 100 su bjects are 
implanted, have their devices activated, and are followed through the 3 -Month 
Visit.  
The primary objective analysis will test the average change in overall pain from 
Baseline to the 3 -Month Visit against no change, using a two -sided, one sampl e t-
test with alpha =0.05.
The secondary objectives are not alpha -controlled; they will be characterized but 
not evaluated with statistical testing.
4. Introduction
4.1. Background
Spinal Cord Stimulation (SCS) was first tested for the management of chronic in tractable pain of the 
trunk and/or limbs in 1967.1The device system used today consists of one or more epidural leads and a 
subcutaneously implanted neurostimulator. The energy delivered from the electrodes on the epidural 
lead modulates pain signals in the nervous syst em. The neurostimulator generates electrical pulses that 
are delivered to the dorsal columns of the spinal cord based on lead location and can be controlled by 
adjusting the programming parameters of amplitude, frequency, and pulse width. Because the tacti le 
sensory neurons in the dorsal columns are stimulated with SCS, paresthesias or a tingling feeling from 
the treatment can be felt during stimulation.
Two branded types of stimulation, HF10 ™and BurstDR ™, have recently come on the SCS market. HF10 
therapy delivers SCS therapy at a frequency of 10 kHz, which is significantly higher than other 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 16of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatecommercial SCS devices with rates between 2 and 1200 Hz. Due to the high frequency used, the HF10 
pulse width is typically around 30 µsec. In contrast, BurstDR is deli vered in a series of five pulses at 500 
Hz,delivered at a 40 -Hz rate . Pulse width is typically set at 1000 µsec. Both of these programming 
algorithms deliver a higher dose of energy than conventional stimulation by increasing the parameters 
of frequency a nd/or pulse width.2A“dose” of therapy can be calculated an d presented as charge per 
second in micro -Coulombs (μC/s).2In fact, the idea of higher energy delivery and energy/sec was 
reported as a possible explanation for the effects of BurstDR .3Other programming parameters may also 
result in “high dose” (HD) stimulation . High dose contrasts with low dose (LD) therapy, which typically 
uses lower energy and frequencies between 30 -100 Hz. Table 1describes an example of parameters of 
HD stimulation .
Table 1SCS Dose
SCS therapy relies on the delivery of energy to a specified stimulation spinal cord target. Conventional 
stimulation has targeted any area of the dorsal columns that result in a comfortable paresthesia 
perception over the painful area. HF10 therapy simplif ied SCS therapy by stagger ing two epidural leads
along the midline from T8 to T11. The typical starting target for HF10 therapy is a bipole at the T9 -T10 
disc space .4This is in accord with a study by Barolat et al. (1993), who determined that targeting the T9 -
T10 implanted “strictly midline” was the “best location” for SCS to treat low back pain without 
stimulation of the chest or abdominal wall.5Barolat (2001) used conventional stimulation parameters at 
T9-T10 in which 68.8% of patients reported fair to excellent pain relief after 1 year of stimulation.6In a 
recent study of HF10, the investigators placed two leads over the T9 -T10 intervertebral space and 
reported that 84.5% of HF10 subjects we re back pain responders , reporting greater than 50% pain 
relief .4Parameter Medtronic 
Device
RangeDescription Conventional High Dose
Dose Variable, 
based on 
settingsA product of pulse width, 
frequency, and current. 
Reported in micro 
Coulombs per second 
(µC/sec), also referred to 
as Charge per second.50 Hz, 400 µsec, 4 
mA = 80 µC/sec1000 Hz, 90 μsec, 4 
mA = 360 μC/sec
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 17of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateWhile the patient outcomes with these stimulation parameters and location is promising, additional 
clinical research is needed to understand the amount of energy and the specific stimulation target that 
will result in the best patient outcomes. 
4.2. Purpose
The purpose of this study is to evaluate the efficacy of spinal cord stimul ation (SCS) therapy using HD 
stimulation parameters while targeting a specific anatomical location .
4.3. Regulatory Study Classification
This on -label, post -market clinical study using the RestoreSensor SureScan MRI and Intellis AdaptiveStim 
Neurostimulation System s,FDA-approved , CE-marked, or licensed/ market released device s, will be 
conducted in up to 30sites and approximately 215 subjects with chronic, intractable pain of the back 
and legs may be enrolled globally .  The study will be conducted in accorda nce with this protocol, the 
ethical principles that have their origin in the Declaration of Helsinki, all applicable regulatory 
requirements ( In the US: 21Code of Federal Regulations [CRF] §50 Protection of Human Subjects ,and 
21CFR§ 56Institutional Review Board [IRB], 21CFR§ 803 Medical Device Reporting ), and International 
Conference on Harmonization (ICH GCP E6) .  Regulatory requirements applicable to individual countries 
outside the US will be included in geography -specific addenda. This study will be posted on 
ClinicalTrials.gov as part of Medtronic’s commitment to full disclosure for ongoing studies that meet the 
requirements for public posting.
Documentation for this study will be produced and maintained to ensure that a complete hi story of the 
study exists.  Documents created for this study, including all versions of original documents, will be 
identifiable and appropriately stored to assure control and traceability of data related to this study .
5. Objectives and Endpoints
5.1. Objectives
5.1.1. Primary Objective(s)
To demonstrate a significant improvement in overall (low back and leg) pain intensity using HD 
stimulation starting at 90-200 µsecand 1000 Hz with lead placement spanning the T9/T10 disc space , 
as measured by the Visual Analog Scal e (VAS), from Baseline to the 3 -Month Visit .
5.1.2. Safety Assessment
This study will characterize a ll device -, therapy -, or procedure -related adverse events and device 
deficiencies from e nrollment to study exit .  
Vectors Post Market Clinical Investigation Plan
#MDT1 7 0 53 Version 4.0    08May 2018 Page 18of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template5.1.3. Secondary Objective(s) 
1.To characterize the overall (low back and leg) pain efficacy responder rate, as measured by the VAS, 
from Baseline to the 3 -Month Visit, with a confidence interval within ±10%
2.To characterize the low back pain efficacy responder rate, as measured by the V AS, from Baseline to 
the 3 -Month Visit, with a confidence interval within ±10%
3.To characterize the leg pain efficacy responder rate, as measured by the VAS, from Baseline to the 3 -
Month Visit, with a confidence interval within ±10%
5.1.4. Additional Measures
 
 
 
 
 
 
 
 
6. Study Design 
This is a prospective, single -arm, multi -center, non -randomized study evaluating the efficacy of SCS 
therapy for pain relief using HD stimulation parameters while targeting a specific anatomical location .  
The study will be conducted at up to 30centers globally .

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 19of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateApproximately 215 subjects are expected to be enrolled in the study to allow for at least 100 subjects to 
complete the 3 -Month Visit. All implanted subjects with devices activated at the Device Activation Visit 
will be followed through the 12 -Month Visit. The study sample size accounts for expected attrition ; 
therefore, subjects who discontinue after implant will not be replaced.
To ensure a widespread distribution of data and minimize center bias in study results, the maximum 
number of subjects that may be implanted at a single site is 25subjects.  . 
There is no minimum enrollment requirement for any study site ; however, each site will be encouraged 
to enroll at least 8subjects . If a si te does not enroll any subjects within three months of activation, they 
may forfeit their participation in the clinical study to another site to ensure timely enrollment.
Selecti on of subjects, treatment of subjects, and evaluation of study data are potential sources of bias. 
Potential sources of bias that may be encountered in this study have been considered and minimized by 
careful study design. Methods incorporated in the study design to minimize potential bias include (but 
are not limited to) the following:
Subjects will be screened to confirm eligibility for enrollment with defined inclusion/exclusion 
criteria
Subject demographics will be collected at baseline to assess possib le characteristics that may 
influence endpoints
To ensure widespread distribution and data among centers , the maximum number of implanted 
subjects per center will be no more than 25. Additionally, centers will be encouraged to enroll at 
least 8 subjects.
Astatistical analysis plan will be developed prior to analyzing data which will document pre -
specified analysis and analysis methods
All study site personnel and Medtronic personnel will be trained on their respective aspects of 
the study using standardize d training materials
All study site personnel will be trained on and required to follow the Clinical Investigation Plan
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 20of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateFigure 1. Vectors study visit flowchart

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 21of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template6.1. Duration
The start of the study for each subject is defined as the date the subject first signs the informed 
consent /HIPAA form orother data protection form as required by local regulations .Enrolled subjects 
will have up to 13scheduled visits. The expected study commitment for each subject is up to 15
months .The ove rall study duration, from first subject enrollment to last subject visit, is expected to last 
approximately 3 -4years. 
6.2. Rationale 
Spinal cord stimulation is a well -established therapy for the treatment of chronic intractable pain, with 
Level I and Level II evidence for the efficacy of the therapy as a treatment of persistent post -lumbar 
surgery pain.7  The efficacy of conven tional spinal cord stimulation in the treatment of back pain has 
lagged leg pain relief associated with SCS.8There is evidence that the T9/T10 intervertebral disc space 
has been a common location to target stimulation for chronic low back pain and leg pain using 
conventional p arameters for over 20 years.5,9–11However, t o date, there have been no large clinical trials 
evaluating outcomes of HD stimulation at frequencies below 10,000 Hz at the T9/T10 intervertebral disc 
space .
7. Product Description
7.1. General
The Medtronic Restor eSensor SureScan MRI and Intellis AdaptiveStim  neurostimulation system will be 
used in this study. All study devices shall be used in accordance with their product labeling and will only 
be used in the geographies in which they are commercially available .  See OUS geography -specific 
addenda for further information as applicable.  For Section 9 (Study Procedures) RestoreSensor 
SureScan MRI will be referred to as RestoreSensor and Intellis AdaptiveStim will be referred to as 
Intellis.  The implanted compone nts of the SCS neurostimulation system include the following:
Model 97714 RestoreSensor SureScan MRI neurostimulator (INS)
Model 97715 Intellis AdaptiveStim neurostimulation system
Model 977D260 Vectris ™1x8 Compact Trial Screening Lead Kit
Models 977A260, 977A275, and 977A290 Vectris ™SureScan® MRI 1x8 Compact Lead Kits
Models 97791 and 97792 Injex™ Anchor Accessory Kits
The non -implanted components of the RestoreSensor SureScan MRI system include the following:
Model 37022 External Neurostimulator
Model 355531 Multi -lead Trialing Cable (MLTC)
Model 8840 N’Vision ®Clinician Programmer 
Model 8870 N’Vision ®Software Application Card
Model 8580 N’Vision® Report Link 
Model 97740 MyStim Patient Programmer
Model 37092 Patient Programmer Antenna
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 22of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateModel 977 54 Recharger Charging System (Includes Model 37751 INS Recharger , Model 
37761 AC Power Supply & applicable accessories)
Model 3550 -54 Patient Waist Belt
Other accessories used ( e.g., tunneling tools, needle kits, wrenches, or screws)
The non -implanted components of the Intellis AdaptiveStim system include the following:
Model 97725 Wireless External Neurostimulator
Model 97745 Patient Controller
Model 375003 Boot for Wireless External Neurostimulator
Model 97755 Recharger
Model 8880T2 Communicator
7.2. Manufacturer
The neurostimulat ionsystem is manufactured by Medtronic , Inc. with operational headquarters in 
Minneapolis, Minnesota 55432 -5604, USA.
7.3. Packaging
All of the devices that will be used in this study have been approved or cleared by the FDA for spinal 
cord stimulation as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The 
devices specified in Section 7.1will b eshipped in their commercially available form in each geography , 
which includes packaging and labeling .  See geography -specific addenda for applicable OUS information.
7.4. Intended Population
In the United States a Medtronic implantable neurostimulation system is indicated for spinal cord 
stimulation (SCS) systems as an aid in the management of chronic, intractable pain of the trunk and/or 
limbs -including unilateral or bilateral pain associated with the following conditions:
Failed Back Syndrome (FBS) or low back syndrome or failed back
Radicular pain syndrome or radiculopathies resulting in pain secondary to FBS or herniated 
disk
Postlaminectomy pain
Multiple low back operations
Unsuccessful disk surgery
Degenerative Disk Disease (DDD)/herniated disk pain refractory to conservative and surgical 
interventions
Peripheral causalgia
Epidural fibrosis
Arachnoiditis or lumbar adhesive arachnoiditis
Complex Regional Pain Syndrome (CRPS), Reflex Sympathetic Dystrophy (RSD), or Causalgia
Refer to geography -specific addenda for OUS information.   
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 23of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template7.5. Product Use
The Medtronic RestoreSensor SureScan MRI and Intellis AdaptiveStim Neurostimulation System and 
related components and accessories are commercially available for SCS in the United States and shall be 
used in accordance with commercial labeling in allgeographies .Exposure to the study product is 
considered from the time the subject is first exposed to the neurostimulation system, during the device 
trial visit, until the product is explanted or the subject discontinues from the study, if later .
7.6. Product Training Requirements
Only i nvestigator s who are trained and e xperience din implanting neurostimulation spinal cord 
stimulation systems will perform the implant procedures required forthis clinical study.
7.7. Product Accountability
All products are considered commercially available and Medtronic will not be providing devices for this 
study. Therefore, device accountability and traceability is not required for this study.
7.8. Product Return
All explanted devices should also be returned to Medtronic for analysis when permissible by local laws 
and regulations. Furthermore, Medtronic requests the return of explanted product from non -clinical 
sources such as funeral homes and will assume responsibility for storage and disposal of the product 
once received.   Please contact your local Medtronic representative for instructions on returning 
products to Medtronic or to receive a Returned Product Mailer Kit.
8. Selection of Subjects
8.1. Study Populatio n
The intended study population is patients with chronic intractable low back and leg pain. 
8.2. Subject Enrollment
Each subject must be in compliance with all of the inclusion /exclusion criteria to be eligible to 
participate in this study.  A subject who does not meet inclusion/exclusion criteria or who discontinues 
prior to implant for any other reason (e.g. fails device trial, cannot be implanted due to hardware, etc.) 
will be considered a screen fail. Once subjects have completed device activation , subject s will continue 
to be followed in the study unless they are an early withdrawal. 
8.3. Inclusion Criteria
1.Willing and able to provide a signed and dated informed consent 
2.At least 18 years old at the time of enrollment
3.Candidate per labeling for an SCS system (trial and implant) as an aid in the management of chronic, 
intractable pain of the trunk and limbs (low back and leg pain)
4.Baseline VAS is ≥ 50 mm for low back pain  
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 24of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template5.Baseline VAS is ≥ 50 mm for legpain
6.ODI score of 21to 80 out of 100
7.On stable (no change in dose, route, or frequency )pain medications (prescribed and over -the-
counter ) being used for back and leg pain , as determined by the investigator, for at least 28 days 
prior to enrolling in the study
8.Willing and able to attend visits and comply with the study protocol
9.Willing and able to not increase their pain medications (prescribed and over -the-counter) being 
used specifically for back or leg pain through the 3 -Month Visit   
Additional Inclusion Criteri on (evaluated at Device Trial -Implant)
1.After paresthesia mapping to confirm proper location at Device Trial , final lead placement spans the 
T9/T10 disc space
2.After paresthesia mapping to confirm proper location at permanent implant , final lead placement 
spans the T9/ T10 disc space
8.4. Exclusion Criteria
1.Previously trialed or implanted with spinal cord stimulator, peripheral nerve stimulator, or an 
implantable intrathecal drug delivery system
2.Expected to be inaccessible for follow -up
3.Subject is currently partici pating, or plans to participate, in another investigational study unless 
written approval is provided by the Medtronic study team
4.Current diagnosis of moderate to severe central lumbar stenosis with neurogenic claudication, as
determined by the investigato r
5.Major psychiatric comorbidity or other progressive diseases that may confound study results , as 
determined by the investigator
6.Serious drug -related behavioral issues (e.g. alcohol dependency, illegal substance abuse), as 
determined by the investigator
7.Pregnant or planning on becoming pregnant (if female and sexually active, subject must be using a 
reliable form of birth control, be surgically sterile ,or be at least 2 years post -menopausal)
8.Unable to achieve supine position
9. Study Procedures 
9.1. Summary of Visits
Specific data and procedure requirements per visit are summarized in Table 4and a flow diagram of the 
device trial is available in Figure 1.A summary of required visits are as follows:
Baseline Visit
Device Trial Day 0 –Lead Placement and initial programming
Device Trial Day 2
Device Trial Day 4 (if necessary)
Device Trial Day 6(if necessary)
Implant
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 25of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateDevice Activation Visit
2-Week Visit
4-Week Visit
6-Week Visit
3-Month Visit
6-Month Visit
12-Month /Final Visit
Telephone calls will be conducted as described in Table 2below.  
All device -, therapy -, or procedure -related adverse events and d evice deficiencies will be collected from 
the point of enrollment through tostudy exit .
Table 2. Protocol Visit Windows
Visit Visit ranges
Baseline Visit NA
Device Trial Day 0 ≤14 days after Baseline visit
Device Trial Day 2 2 + 2 days after Device Trial Day 0
Device Trial Day 4, if necessary 2 + 2 days after Device Trial Day 2
Device Trial Day 6 , if necessaryMust occur 2 days after Device Trial Day 4 Visit and 
before or on Device Trial Day 10
Implant Visit ≤30 days after end of device trial
Device Activation Visit (Day 0) 9 -16days after implant ; pending woun d healing
1-Week Telephone Call 7 ±3 days after Day 0
2-Week Clinic Visit 14 days ± 3 days after Day 0
3-Week Telephone Call 21 ±3 days after Day 0
4-Week Clinic Visit 28days ± 3 days after Day 0
5-Week Telephone Call 35 ±3 days after Day 0
6-Week Clinic Visit 42days ± 3days after Day 0
7-Week Telephone Call 49 ±3 days after Day 0
8-Week Telephone Call 56 days ± 3days after Day 0
9-Week Telephone Call 63 ±3 days after Day 0
10-Week Telephone Call 70 days ± 3days after Day 0
11-Week Telephone Call 77 ±3 days after Day 0
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 26of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateVisit Visit ranges
3-Month Clinic Visit 90 days ± 10 days after Day 0
3.5-Month Telephone Call 105 days ± 15days after Day 0
4.5-Month Telephone Call 135 days ± 15days after Day 0
5.5-Month Telephone Call * 165 days ± 15days after Day 0
6-Month Clinic Visit 180 days ± 15 days after Day 0
6.5-Month Telephone Call * 195 days ± 15days after Day 0
7.5-Month Telephone Call 225 days ± 15days after Day 0
8.5 Month Telephone Call 255 days ± 15days after Day 0
9.5-Month Telephone Call 285 days ± 15days after Day 0
10.5 -Month Telephone Call 315 days ± 15days after Day 0
11.5 -Month Telephone Call * 345 days ± 15days after Day 0
12-Month /Final Clinic Visit 360 days ± 15 days after Day 0
*For instances where the monthly telephone call window overlaps the clinic visit window, if the clinic 
visit occurs within the telephone call window, the telephone call is not required .  
9.2. Baseline Visit
Subjects are considered enrolled at the time the study -specific informed consent /HIPAA form or other 
data protection form as required by local regulations is signed.  At the Baseline visit,subjects will be 
consented and if they agree to participate they will be assessed for eligibility to the study -spec ific 
inclusion/exclusion criteria. Each subject must be in compliance with all of the inclusion /exclusion
criteria to be eligible to participate in this study .  No study -related procedures or testing will be 
conducted prior to completing the consenting pro cess of a subject. Female subjects of child -bearing 
potential will be administered a urine pregnancy test at this visit.  A subject who has a positive urine 
pregnancy test will be exited from the study according to Section 9.19 .  Once a subject is enrolled, if 
they are determined to be ineligible for the study, or if they withdraw early, a study exit eCRF must be 
completed.  Subjects will complete theVAS for overall ( low back and leg) pain, low back pain, and leg 
pain . The VAS will be scored to assess subject eligibility per the inclusion criteria. Subjects must have a 
VAS score ≥ 50 mm for low back pain, a VAS score ≥ 50 mm for leg pain, and an ODI s core that is 
between 21 to 80 to continue in the study.   If subjects are in compliance with the inclusion and exclusion
criteria , their low back and leg pain history and surgical history will be collected at this visit. Enrolled 
subjects may not be rescree ned.   Subjects that meet the minimum pain score criteria will also be 
scheduled for a device trial and complete the required assessments (see below ).  Subjects will also be 
asked to set an objective goal for their therapy related to a desired outcome or ac tivity i.e., the ability to 
stand and wash di shes or walk around the block .  
Vectors Post Market Clinical Investigation Plan
#MDT1 7 0 53 Version 4.0    08May 2018 Page 27of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateData collection requirements for the Baseline Visit :
VAS
Inclusion/exclusion criteria
Demographics
Back and leg pain/surgical history
Urine p regnancy test results, if applicable
EQ-5D-5L
ODI
Activity goal
Pain medications
AEs
9.3. Device Trial (≤ 14 days post-Baseline )
The Device Trial has t hree phases:
Phase I: Implant and Programming (Trial –Day 0)
Phase II: Evaluation of HD Programming (Trial Days 0 –
4)
Phase III: Evaluation of Physician Preference Programming (Trial Days 4 –10), if necessary
Implant and Programming ( Trial –Day 0)
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 28of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 29of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatee.For Intellis: End session , exit application , generate and obtain report
During this visit, subjects will be provided with a patient programmer and ENS and educated on their
use.  During the device trial, subjects will be allowed to change the amplitude. However, changes to the 
frequency and pulse width by the subject will not be allowed and will be locked on the patient 
programmer.   
Data collection requirements for the Device Trial Day 0 :
Device information
Fluoroscopy/x -rayimages annotated with vertebral marker(s)
Final program settings
Initial and final device interrogation reports
Level of conus medularis (if available)
Pain medications
AEs/device deficiencies
Day 2 Visit (2 + 2 Days from Device Trial Day 0 )
At the Day 2 Visit, subjects will be asked to report their improvement in ove rall pain compared to 
baseline. It is r ecommended that the Day 2 Visit be, at least, 48 hours after Trial Day 0.
If a subject reports ≥ 50% improvement in overall pain compared to baseline at the Day 2 
visit, the trial will be deemed successful and trial leads will be explanted.
If a subject d oes not report ≥ 50% improvement in overall pain compared to baseline at the 
Day 2 Visit, they will be reprogrammed to move the bipole up one electrode and schedule a 
Day 4 Visit.     
Data collection requirements for the Day 2 Visit
Percent Improvement in Overall Pain Assessment
Final program settings, if reprogramming occurs
Initial and final device interrogation reports
Pain medications 
AEs/device deficiencies
Day 4 Visit (2 + 2 Days from Day 2 Visit ; if necessary)
At the Day 4 Visit, subjects will be asked to report their improvement in overall pain compared to 
baseline .  It is recommended that the Day 4Visit be, at least, 48 hours after the Day 2 Visit.   
If a subject reports ≥ 50% improvement in overall pain compared to baseline at the Day 4 
visit, the trial will be deemed successful and trial leads will be explanted.
If a subject does not report ≥ 50% improvement in overall pain compared to baseline at the 
Day 4 Visit , they will be p rogrammed to physician preference settings (see Physician 
Preferen ceProgramming Instructions ).
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 30of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
Day 6 Visit (Must occur 2 days after Day 4 Visit and within 10 days of Trial Lead Implant ), if 
necessary

Vectors Post Market Clinical Investigation Plan
#MDT1 7 0 53 Version 4.0    08May 2018 Page 31of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAt the Day 6 Visit, which must occur by day 10 of the device trial, subjects will be asked to report their 
improvement in overall pain compared to baseline .  Trial leads will be explanted and subjects will be 
exited from the study. It is recommended that the Day 6 Visit be a
t least 48 hours after the Day 4 Visit.
Data collection requirements for the Device Trial Day 6 :
Percent Improvement in Overall Pain Assessment
Final program settings
Initial and final device interrogation reports
Pain medications
AEs/device deficiencies
Trial Lead Explant
All device interrogation report s(initial and final) will be c ollected and then leads will be explanted.  Trial 
lead explant must occur within 10days of Trial Lead Implant .
9.4. Implant Visit ( ≤30 days from trial lead explant )
 
 
  
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 32of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
  
 
Data collection requirements for the Implant Visit :
Device information
Serial/lot numbers fo r leads and INS
Fluoroscopy/x -rayimages annotated with vertebral marker(s)
Initial and final device interrogation reports
Pain medications
AEs/device deficiencies
9.5. Device Activation Visit (Day 0; 9 – 16 days after implant )
The Device Acti vation Visit will take place 9 –
16days after implant, pending wound healing. If wound 
has not healed, reschedule the Device Activation Visit.  Device Activation is considered Day 0 for the 
purpose of calculating the monthly follow -up visits and phone calls.  Lead location (lateral and AP) may 
be captured via fluoroscopy/x -rayannotated with vertebral marker(s) .  U
se the most current image to 
prog ram the subject’s device based on Programming Algorithm below ( Table 3).  During this visit, 
subjects will be educated on the use of their patient programmer and rech arger . 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 33of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7 0 53 Version 4.0    08May 2018 Page 34of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
Table 3. Recommended Permanent Implant Programming Algorithm
 
  
Data collection requirements for the Device Activation Visit :
Fluoroscopy/x -ray images annotated with vertebral marker(s) , if collected
Initial and final device interrogation reports
Pain medications
AEs/device deficiencies
9.6. 2 -Week , 4-Wee k, 6-Week and3-, 6-,and 12 -Month Clinic 
Visits
Visits will occur at 2, 4 and 6 weeks and 3, 6 and 12 months post -device activation. At the 2 -WeekVisit
or 4-Week Visit, if the 2 -Week Visit is not at least 30 days after implant, the subject will have the 
accelerometer in their device oriented in all positions and AdaptiveStim enabled .  VAS will be collected 
at all visits. EQ-5D-5L, ODI, PGIC, and SSA will be assessed at the 3-, 6-and 12 -Month Visit s. The 
Paresthesia Assessment , and Rechargi ng Que stionnaire will be collected at the 3 -and 12 -Month Visits. 
The Activity Goal Assessment will be collected at 2-W eek, 4-W eek, 6-Week and 3 -Month Visits .  Data for 
the primary endpoint will be collected at the 3 -Month Visit.  

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 35of 80
 
 
  
 
   
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 36of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
Data collection requirements for the 2-Week, 4 -Week, 6
-Week and 3-, 6-, and 12 -Month Clinic Visits :
VAS (all follow- up visits)
EQ-5D-5L(3-, 6-12-Months)
ODI (3-, 6-, 12-Months
SSA (3, 6 -, 12 Months)
PGIC (3-, 6-, 12 Months)
Activity Goal Assessment (2-Week, 4 -Week, 6-Week, and 3-Month)
Paresthesia Assessment (3-, 12-Month s)
Recharger Questionnaire ( 3-, 12-Months )
Fluoroscopy/x -ray annotated with vertebral marker(s) , if applicable
Initial and final device interrogation reports
Pain medications
AEs/device deficiencies
9.7. Telephone Calls ( 1, 3, 5, 7, 8, 9,10 and 11 weeks post -
device activation; Monthly Telephone Calls at 3.5, 4.5, 5.5, 
6.5, 7.5, 8.5, 9.5, 10.5, 11.5 Months post-3-Month Visit )
Subjects will be assessed for AEs (new or existing) and asked about any pain medication changes.  They 
will also beasked to confirm that their stimulator is on and the amplitude reported on their patient 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 37of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templateprogrammer .If the subject is not satisfied with their pain relief, they will come in for an unscheduled 
visit.  
Data collection requirements for the Telephone Calls :
Pain Relief Assessment
Amplitude for active group
Pain medications
AEs/device deficiencies
9.8. Unscheduled Visits:
Unscheduled visits may occur if programming changes are required to correct programmin g errors, to 
reprogram to optimize pain control (see Reprogramming Instructions in section 9.6), or for an AE .  
Whenever feasible, subjects should have their devices interrogated. If a subject was experiencing ≥50%
reduction in pain at a previous visit and no longer is, a fluoroscopy/x -ray annotated with vertebral 
marker(s) may be taken to assess for possible lead migration. 
Data collection requirements for the Unscheduled Visit :
VAS
Reason for the visit
Initial and final device interrogation reports , if applicable
Fluoroscopy/x -rayannotated with vertebral marker(s) , if applicable
Pain medications
AEs/device deficiencies
9.9. System Modifications:
System modifications (e.g. lead or device revision, replacement, or explant) may occur due to ineffective 
or loss of therapy , adverse event, device deficiency , or subject concerns that are not correctable by 
programming.  In the event of a system modification, the follow -up schedule for the subject will remain 
unchanged.   If the neurostimulator requires replacement, contact a member of the Medtronic study 
team as the decision to allow re -implant will be handled on a case -by-case basis. If the system is 
explanted, the explanted system should be returned to Medtronic (Refer to Device Product Return, 
Section 7.8).
Data collection requirements for a system modification :
Initial and final interrogations from old and new INS uploaded to NPU , if replaced and 
subject remains in the study
If any portion of the implanted system is replaced, record all changes in source 
documentation and on the system modification eCRF (e.g. new lead model/serial number)
AEs/device deficiencies
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 38of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template9.10. Study Exit
Normal study completion occurs when the subject has co mpleted the required study visit sthrough the 
12-Month Visit (refer to required procedures described in Section 9.6),at which time the subject will 
end their part icipation in the study and site personnel will then complete a study exit eCRF. If the 
subject is an early withdrawal, refer to Withdrawal of Subjects, Section 9.19 .
9.11. Schedule of Events
Table 4: Schedule of Events
Study Procedures, Tasks, 
and Data Collection 
(row) by Visit (column)
Baseline Visit
Device Trial (Trial Day 0) Visit
Device Trial Day 2Visit
Device Trial Day 4 Visit
Device TrialDay 6 Visit
Implant Visit
Device Activation Visit (Day 0)
2-, 4-, 6-week, 3-, 6-, and 
12-Month/Final Visit
Post-implantPhone Calls 
Unscheduled Visits
Informed Consent Process √
Demographics √
Inclusion/Exclusion Criteria √
Urine Pregnancy Test √
VAS –overall, low back, and 
leg√ √ √
Low back and Leg 
Pain/Surgical History√
Activity Goal √ √a
EQ-5D-5L √ √b
ODI √ √b
Level of conus medularisf √
Final Program Settings √ √c √c √c
Percent Improvement in 
Overall Pain√ √d √d
Pain Relief Assessment √
Fluoroscopy/x -ray
annotated with vertebral 
marker(s)√e √ √f √f √f
Amplitude of Active Group √
Device information (model, 
serial /lot number)√ √
Paresthesia Assessment √g
Recharging Questionnaire √g
PGIC √b
Subject Satisfaction 
Assessment (SSA)√b
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 39of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateStudy Procedures, Tasks, 
and Data Collection 
(row) by Visit (column)
Baseline Visit
Device Trial (Trial Day 0) Visit
Device Trial Day 2Visit
Device Trial Day 4 Visit
Device TrialDay 6 Visit
Implant Visit
Device Activation Visit (Day 0)
2-, 4-, 6-week, 3-, 6-, and 
12-Month/Final Visit
Post-implantPhone Calls 
Unscheduled Visits
Initial and final device 
interrogation reports√ √ √c √c √ √ √ √c
Collect AE/DD √ √ √ √ √ √ √ √ √ √
Pain Medications √ √ √ √ √ √ √ √ √ √
aActivity goal performed at 2, 4, 6 -week and 3 -month visit
bEQ-5D-5L, ODI, PGIC and SSA p erformed at 3, 6 and 12 -month visits 
cPerform activity only if unit reprogr ammed
dIf visit performed
eAt trial i mplant a nd if acquired in recovery room
fIf acquired
gParesthesia questionnaire and recharging questionnaire p erformed at 3 and 12 -month visit
9.12. Subject Screening 
Subjects may be recruited through the investigator’s practice and referring physicians.   It is 
recommended to recruit subjects who live within a reasonable distance from the site.
Potential subjects may be identified through chart revie ws or as new or existing patients attend clinic 
visits. If subjects are recruited from outside the investigator’s practice, sites are to ensure that 
appropriate release for access to the subject’s records (paper and/or electronic) is obtained. Any subject
recruitment materials disseminated to subjects (advertisements, handouts, posters , social media ) must 
be approved by the IRB/ECprior to use. 
Recruited subjects will be screened by the Principal Investigator or authorized site personnel by 
reviewing the study inclusion and exclusion criteria.  All subjects must be consented in accordance with 
the protocol prior to any study -specific procedures.  Subjects who do not meet allof the inclusion 
criteria or who meet any of the exclusion criteria cannot be rescreened.
9.13. Prior and Concomitant Medications
Only medications used for the treatment of back and/orleg pain will be collected during the study . Only 
subjec ts who are on a stable dose (no new medications , discontinued, or changes in dose , rout e, or 
frequency ) of all prescribed and over the counter pain medications for low back and/orleg pain , in the 
opinion of the PI, for at least 28 days prior to screening will be eligible for participation in the study.  
Subjects will notbe allowed toincrease their pain medications (including prescribed and over -the-
counter) specifically for back and leg pain , as defined above, through the 3 -Month Visit unless there is a 
need to mitigate a safety concern (e.g. adverse event). Decreases in pain medications are allowed after 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 40of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templateenrollment .  Any changes to subject’s pain medications while they are enrolled in the study will be 
documented in the subject’s medical records and the pain medications eCRF. 
The addition of pain medications for the relief of surgical discomfort after device trial and implant 
procedures is allowed. Pain medications prescribed for post -operative pain management are not 
considered an increase in pain medi cations if the medication is ceased prior to the date of the Device 
Activation Visit . 
9.14. Subject Consent
Investigators shall consider for enrollment all subjects who meet eligibility requirements for study
participation to avoid any bias in the subject popul ation. Prior to enrolling subjects, each investigational 
site’s IRB /ECwill be required to approve the CIP, the informed consent form (ICF) and HIPAA/data 
protection authorization or other privacy language (where required by law), and any other written stu dy 
information to be provided to the subjects (e.g. CA Bil l of Rights if applicable , subject assessment setc.). 
The document(s) must be controlled (i.e. version number and date) to ensure it is clear which version(s) 
were approved by the IRB /EC. Any adaptation of the informed conse nt form must be reviewed by
Medtronic and approved by the IRB /ECprior to enrolling subjects. The ICF will be provided under 
separate cover .
Patient informed consent is defined as legally effective, documented confirmation of a subject’s 
voluntary agreement to participate in a clinical study after information has been given to the subject on 
all aspects of the clinical study that are relevant to the subject’s decision to participate. The informed 
consent process will be perf ormed in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and in accordance with 21 CRF Part 50 or applicable local regulation.     
Prior to entering the study, the principal investigator, or appropriately deleg ated designee, will explain 
to each subject all aspects of the clinical investigation that are relevant to the subject’s decision to 
participate throughout the clinical investigation including, but not limited to, the following: purpose and 
nature of the s tudy, study procedures, expected study duration, available alternative therapies, and the 
benefits and risks involved with study participation and the potential treatment.
The investigator shall seek such consent only under circumstances that provide the p rospective subject 
sufficient opportunity to consider whether to participate ,and that minimize the possibility of coercion 
or undue influence. No informed consent, whether oral or written, may include any exculpatory 
language through which the subject is made to waive or appear to waive any of the subject’s legal rights, 
or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability 
for negligence. 
Subjects are considered enrolled at the time the study -speci fic ICFis signed. Informed c onsent must be 
obtained from the subject prior to initiation of any study -specific procedures . Subjects must be able to 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 41of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatepersonally sign and date the consent form to participate in this study. Signing and dating of the ICFor
HIPAA authorization or other data protection form bya legally authorized representative will not be 
permitted for this study. Subjects will be required to sign and date a HIPAA authorization or other dat a 
protection form as required by local regulations before participating sites can collect, use and submit
subject information to the study sponsor. The Consent Form and Authorization to Use and Disclose 
Personal Health Information/ Research Authorization/other legally required privacy languagemust be 
given to the subject in a language he/she is able to read and understand. 
If the informed c onsent form is obtained the same day the subject begins participating in study -related 
procedures, it will be documented in the subject’s case history that consent was obtained prior to 
participation in any study -related procedures
The original signed ICFmust be filed in the hospital/clinical chart and /orwith the subject’s study 
documents. A copy of the informed conse nt form and signed Authorization to Use and Disclose Personal
Health Information/Research Authorization/other legally required privacy language must be provided to 
the subject.
The informed conse nt form and Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other legally r equired privacy language must be available for 
monitoring and auditing. 
Any changes to a previously approved informed conse nt form throughout the course of the study must 
be submitted and approved by Medtronic and the IRB/ECreviewing the application befo re being used to 
consent a prospective study subject. The document(s) must be controlled (i.e. versioned and dated) to 
ensure it is clear which version(s) were approved by the IRB/EC. 
The investigator must notify the subject of any significant new finding s about the study that become 
available during the course of the study which are pertinent to the safety and well -being of the subject, 
as this could impact a subject’s willingness to participate in the study. If relevant, approval may be 
requested from su bjects to confirm their continued participation.
9.15. Assessment of Efficacy
Subject assessments will be performed by appropriately trained, qualified and delegated site personnel
according to the usual practices of the site.      
9.15.1. Single -day Visual Analog Scal e (VAS)
Pain will be assessed by a single -day VAS (0 –100 mm).  The VAS will be used to evaluate the primary 
and two secondary study endpoints with 0 mm meaning “no overall, low back, or leg pain” and 100 mm 
meaning “worst overall, low back, or leg pain imaginabl e.”  Subjects will be asked to report pain 
intensity “in the last 24 hours” by marking a line perpendicular to the VAS line at the point that 
represents their pain intensity.  Site personnel will determine the score by measuring the distance (mm) 
on the 10 0-mm line between the left, “no pain” anchor and the subject’s mark, measuring the total 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 42of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatedistance of the line (to ensure that it is 100 mm) and dividing the distance from the “no pain” mark to 
the subject’s mark by the total distance of the line. The score d VAS ranges from 0 –100. The VAS will be 
administered at the Baseline, Follow -upVisits ( 2-Week, 4 -Week , 6-Week and 3-, 6-and 12 -Month Visits) , 
and Unscheduled Visits .  The VAS data will be the basis for verification of certain study entry criteria at 
the Baseline Visit and for calculation of the primary study endpoint .  
9.15.2. Percent Improvement in Overall Pain Assessment
Subjects will be asked their percent improvement in overall pain from 0 –100% at Device Trial D ay 2,
Device Trial Day 4 , and Device Tri al Day 6 .
9.15.3. Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change ( PGIC ) version 2 , which measures the subject’s impression of 
change12,will be administered at the 3 -,6-,and 12 -Month Visitsprior to device interr ogation.  The PGIC 
isa 7-point scale used by patients to report their overall assessment of change in status since beginning 
treatment which will be defined as when the device was turned on .The P GIC consists of the following 
question:
Since beginning treatment ,at this clinic (in this study), how would you describe the change (if any) in 
ACTIVITY LIMITATIONS, SYMPTOMS, EMOTIONS, and OVERALL QUALITY OF LIFE related to your pain ful
condition ? (tick ONE box)
1.No change (or condition has got tenworse)
2.Almost the same, hardly any change at all
3.A little better, but no noticeable change
4.Somewhat better, but the change has not made any difference
5.Moderately better, and a slight but noticeable change
6.Better, and a definite improvement that has made a real and worthwhile difference
7.A great deal better, and a considerable improvement that has made all the difference
9.15.4. Pain Relief Assessment
Subjects will be asked if they are satisfied with pain relief onthe weekly and monthly phone calls 
following device activation .Verbal responses will be documented by qualified, trained, and delegated 
site personnel during the call.
9.15.5. Recharging Questionnaire
This questionnaire will be administered at the 3 -and 12 -Month visits and is designed to capture 
information about the frequency and typical duration of recharging sessions experienced by s ubjects.  
9.15.6. Paresthesia Asses sment
This assessment will be administered at 3-and 12 -Month Visits and is utilized to obtain subjec t feed back 
on whether or not they have experienced the sensation of paresthesia, and if so, whether or not it was 
uncomfortable . 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 43of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template9.15.7. Subject Satisfaction Assessment (SSA)
This assessment will be administered at the 3 -, 6-and 12 -Month Visits and is utilized t o obtain subject 
feed back on whether they would recommend the therapy to other patients suffering from similar pain, 
and to obtain feed back on their overall satisfaction with the therapy . 
9.15.8. European Quality of Life -Five Dimensions
This assessment will be ad ministered at the Baseline Visit and 3 -, 6-and 12 -Month Visits. The European 
Quality of Life –Five Dimensions (EQ -5D), version 5L, is a standardized measure of health status 
developed by the EuroQol Group and a widely used validated tool to determine hea lth-related quality of 
life.13The EQ -5D-5Ldescriptive system consists of 5 dimensions: mobility, self -care, usual a ctivities, 
pain/discomfort, and anxiety/depression. Each dimension has 5 levels of severity: no problems, slight 
problems, moderate problems, severe problems, extreme problems. The subject will be asked to 
indicate his/her health state by selecting the most appropriate statement in each of the 5 dimensions. 
9.15.9. ODI
This assessment will be administered at the Baseline Visit and 3 -, 6-and 12 -Month Visits. The ODI 
(version 2) is one of the most highly recommended measure s for patients with spinal disorders.14The 
validated questionnaire consists of 10 subject -reported sections on the ability to perform activities of 
daily living.
9.15.10. Activity Goal 
The Activity Goal will be administered at the Baseline Visit ,2-Week, 4 -Week , 6-Week and 3 -Month 
Visits. It is used to assess progress towards a specific , realistic activity goal chosen by the subject at the 
Baseline Visit.If Baseline goal is obtained, then the subject will be asked to set a new goal and so on 
through the 3-Month Visit.
9.15.11. Back Pain/Surgical History and Demographics
Subject demographics ,back and leg pain/surgical history and primary pain diagnosis will be c ollected at 
the Baseline visit. This information must be documented within their medical records and reported on 
the study eCRF s.
9.16. Assessment of Safety
Subjects willbe assessed from enrollment through the end of the study for AEs related to the following:
The implanted SCS system, accessories and surgical procedure s
SCS therapy
In addition, all device deficiencies reported during the study will be collected .
9.17. Recording Data
This study will be utilizing a remote data capture (RDC) system to collect study required Case Report 
Form (CRF) information. Electronic CRFs (eCRFs) will be provided by the sponsor; required data will be 
taken from source documents and entered into the study database via the eCRFs by the appropriately 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 44of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatedelegated site personnel, in accordance with applicable regulations.   Source documentation for VAS and 
subject assessments will be captured in a paper format and completed confidentially by the subject 
only . Datafrom the paper assessments will be entered into the database by delegated site personnel
after ensuring the completeness and accuracy of the data .  
The Principal Investigator or appropriately delegated individuals are responsible for entering data for
the study onthe eCRFs.  The Principal Investigator or delegated Sub-Investigator (physician only) is 
required to approve all data on eCRFs via electronic signature .
9.17.1. Programming Data
Through device interrogation s with the 8840 N’Vision® Clinician Programmer for RestoreSensor 
SureScan MRI Neurostimulation system and the 8880T2 Communicator for the Intellis AdaptiveStim 
Neurostimulation system, parameter data (e.g., session data files ) will be collected from the
neurostimulator .
Report Link is a commercially available tool , which will be used during this study for the Rest oreSensor 
SureScan MRI Neurostimulation system, that allows clinicians to electronically transfer and save session 
data files as a PDF document from the 8840 N’Vision ® Clinician Programmer to a computer at their study 
site. The Intellis AdaptiveStim Neuros timulation system uses an app, Clinical Data Upload, on the 8880T2 
Communicator to electronically transfer session data files as PDF documents to a computer at their 
study site. The PDF files can be printed to local or network printer and stored in electr onic medical 
record systems and uploaded into the Neuro Programmer Upload (NPU ) application.
NPU is an application designed to capture and store programmer interrogation output reports (e.g., 
session data reports )from the 8840 N’Vision Clinician Programme ror the Intellis AdaptiveStim 
Neurostimulation system , extract and store the data in the Medtronic NPU database for analysis and 
reporting .
9.17.2. Fluoroscopy/x -ray imaging
Fluoroscopy/x -rays will be obtained at Device Tr ial Implant and Permanent Implant .  Fluoroscopy/x -rays 
may be obtained at the Device Trial in the recovery room (after subject is dressed prior to 
programming) , at the Device Activation visit, or at any time the investigator feels is necessary. Any 
images collected for the study will be annotated with a vertebral marker .   
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 45of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAn imaging Manual with instructions on how to transfer the images to Medidata Solutions will be 
provided to the study sites. Medidata Solutions will send d e-identified images to Medtronic . Medtronic 
willstore the images in a secure document management system, and a qualified reader will evaluate the 
images to define and characterize the locations of the lead and active contacts with respect to 
anatomical landmarks as w ell as for future evaluation by Medtronic.    
9.18. Deviation Handling
A deviation is defined as an instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the clinical investigational plan. The investigator is not allowed to deviate from the CIP, 
except under emergency circumstances to protect the rights, safety and well -being of human subjects.
All study deviations must be reported on the eCRFs regardless of whether medically justifiable, pre -
approved by Medtronic, an inadve rtent occurrence, or taken to protect the subject in an emergency. 
Study deviations must be reported to Medtronic as soon as possible upon the site becoming aware of 
the deviation. Reporting of deviations must comply with IRB/EC policies, local laws, and/ or regulatory 
agency requirements. 
In the event the deviation involves a failure to obtain a subject’s consent or is made to protect the life or 
physical well- being of a subject in an emergency, the deviation must be reported to the IRB/ECas well as 
Medt ronic within five (5) working days.
In situations where the investigator anticipates, contemplates, or makes a conscious decision to deviate
from the CIP, the Investigator must submit in writing to Medtronic, his/her request to deviate from the 
CIP. Prior written approval from Medtronic is expected. In such situations , if the deviation affects a 
subject’s rights, safety and well -being, or the scientific integrity of the study, prior approval from IRB/EC
is also required. 
Prior approval from Medtroni cis not required when a deviation is necessary to protect the rights , safety
or well -being of a subject in an emergency or in unforeseen situations beyond the investigator’s control 
(e.g. subject failure to attend scheduled follow -up visits, inadvertent loss of data due to computer 
malfunction, inability to perform required procedures due to subject illness).
Medtronic is responsible for analyzing deviations, assessing their significance, and identifying any 
additional corrective and/or preventive actions (e.g. amend the Clinical Investigation Plan, conduct 
additional training, or terminate the investigation). Repetitive or serious investigator compliance issues 
may result in initiation of a corrective action plan with the investigator and site, and in some cases, 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 46of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatenecessitate suspending enrollment until the problem is resolved or ultimately terminating the 
investigator's participation in the study.
Examples of study deviations include but are not limited to the following:
Failure to obtain informed consent o r HIPAA authorization prior to study enrollment, failure 
to re -consent when new risks/procedures added, use of an outdated consent, or unqualified 
or non -delegated personnel performing consent process
Violation of inclusion/exclusion criteria
Failure to co llect protocol required assessments or failure to perform protocol required 
procedures (e.g., VAS data, subject assessment missing)
Missed visits
Visits outside of window
Lack of programmer data upload or device interrogation printout
Use of expired device or unapproved device
Unauthorized personnel performing study procedures
9.19. Subject Withdrawal or Discontinuation 
A subject has the right to withdraw from the study at any time and for any reason without prejudice to 
his/her future medical care by the princi pal investigator or institution.  Subjects will be provided 
standard medical care by their physician after their study participation ends .
The study sample size accounts for expected attrition, thus subjects that discontinue after implant will 
notbe repl aced.
If a subject is withdrawn from the study, the reason for withdrawal shall be recorded on astudy exit
eCRF and in the subject’s medical record.  Examples of reasons for study discontinuation include, but are 
not limited to, the following:
Eligibility criteria not met
Pregnancy
Failure to follow study requirements
Subject death
Subject lost to follow -up (LTFU)
Subject voluntarily withdraws from the study
Adverse events 
Normal study completion
A study exiteCRF will be completed for any enrolled subje ct who permanently discontinues from the 
study or completes the protocol -required study follow -up and has completed the study. 
In the case that the subject is determined to be lost to follow -up, details of a minimum of three
attempts and the method of attempt (e.g., two by phone and one by certified letter ) to contact the 
subject must be recorded in the subject’s medical records. In addition, requirements set forth by the 
governing IRB/ECmust be followed.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 47of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateThe investigator should make all attempts to conduct a discontinuation visit prior to subject withdrawal 
ifthe subject is withdrawn after the Device Activation Visit and outside of a protocol -required visit .All 
eCRFs should be completed for visits that occurred prior to the subject’s withdrawal. In addition, 
regardless of when the discontinuation occurs, the subject should be asked to complete all 12 -
Month/Final Visit procedures, if the subject is willing, in order to obtain final assessments for the study.  
A study exit eCRF must also be completed.
Table 5. Data collection requirements for subject withdrawal
Time of Early Withdrawal Procedures Required
Prior to Device Activation Complete appropriate visit eCRFs based on the visits completed (e.g.
Baseline, Device Trial etc.) prior to discontinuation and the study exit eCRF.
After Device Activation and prior 
to the 12 -Month /Final VisitComplete all appropriate visit eCRFs based on visits completed prior to the 
discontinuation, the 12-Month /Final V isit eCRF (ifsubject is wil ling), and 
study exit eCRF.
9.20. Pregnancy
The safety of SCS has not been established for pregnant women, for an unborn fetus, or during 
childbirth. If a subject is able to become pregnant and is sexually active, documentation of medically 
acceptable birth control must be present in the medical records. In the event that a subject becomes 
pregnant during the study , it is not considered an AE; however , the study center must immediately 
inform Medtronic study personnel and perform th e following activities:
The investigator will instruct the subject to turn the stimulator “OFF” and to return to the 
site for a visit as soon as possible. The subject will be exited from the study.
The study center must complete a Study Exit eCRF and final interrogation and upload 
reflecting therapy suspension.
The Principal Investigator should notify the IRB per the study center’s specific requirements .
10. Risks and Benefits
10.1. Potential Risk s
Spinal Cord Stimulation therapy is a reversible procedure (i.e., the system can be turned off or removed 
in most cases) with stimulation parameters that are adjustable to minimize or reverse complications and 
maximize therapeutic effects.  The RestoreSenso r SureScan MRI and Intelis AdaptiveStim 
Neurostimulation system sarecommercially available for treatment of chronic intractable pain.  The 
risks associated with the RestoreSenso r SureScan MRI and Intellis AdaptiveStim Neurostimulat ion 
system sare included in commercial product information .  Systems will only be used in geographies 
where they are commercially available.   There are no expected new or increased risks associated with 
this clinical study.   
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 48of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateThere may be additional risks related to the use of Medtronic neurostimulation systems , other than the 
ones described be low, that are not yet known.
10.1.1. Risks of Surgery
Implanting a neurostimulation system has risks similar to spinal procedures, including spinal fluid leak 
(spinal fluid collection under the skin), headaches, swelling, bruising, bleeding, infection, or paralysi s. 
Subjects on anticoagulation therapy may be at higher risk for problems a fter surgery such as hematomas 
that could result in paralysis.
10.1.2. Spinal Cord Stimulation Risks
The implantation of a spinal cord stimulation system involves risks that are similar to other spinal 
procedures. In addition to those normally associated with surgery, implantation or use of a 
neurostimulation system includes, but is not limited to, the following risks:
Allergic or immune system response to the implanted materials
Infection
Lead or neurostimulator erosion through the skin or migration
Leakage of cerebrospinal fluid
Loss of pain relief may return patients to their underlying pain condition
Persistent pain at the neurostimulator site
Placement of the epidural lead is a surgical procedure that may expose patients to risks of 
epidural hemorrhage (bleeding), hematoma, or paralysis
Radicular chest wall stimulation
Seroma (fluid collection in pocket where stimulator is placed) or hematoma at the 
neurostimulator site
Change in stimulation, possibly related to cellular changes around the electrode(s), shifts in 
electrode position, loose electrical connections, lead fractures, which has been described by 
some patients as uncomfortable stimulation (jolting or shocking sensation)
Over time there could be changes in the level of symptom control. In most cases, the 
physician can correct these changes without surgery.
Formation of excessive tissue around the lead in the epidural space can result in delayed 
spinal cord compression and pa ralysis, requiring surgical intervention. Time to onset can 
range from weeks to many years after implant.
The safety of this therapy is unknown for pregnancy, unborn fetus, or delivery
Stimulation -dependent gastrointestinal symptoms such as diarrhea, incon tinence or 
constipation
Stimulation -dependent bladder symptoms such as urinary retention, incontinence or 
frequency
Unexpected changes in stimulation -Electromagnetic interference, changes in posture, and 
other activities can cause a perceived increase in stimulation
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 49of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 50of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateLow battery charge level –Charge theneurostimulator when you see a Low battery screen displayed on 
the patient programmer or recharger .  If the battery charge level is at 0 ,the device should be recharged 
to avoid therapy delivery falling to 0 .  For RestoreSensor SureScan MRI Neurostimulator if the battery 
remains in a discharged state, it continues to lose charge and it will become overdischarged. If the
RestoreSensor SureScan MRI Neurostimulator battery is allowed to overdischarge, the recharger may 
not be able t o recharge or commun icate with the neurostimulator; however, your doctor may be able to 
restore the battery function.  For RestoreSensor SureScan MRI Neurostimulator, follow the instructions 
in the model 37751 Recharger Charging System Manual to recharge t he neurostimulator battery .
Recharger use –Check for skin irritation or redness near the neurostimulator during recharging. Do not 
sit or lie on the antenna or apply excessive pressure to the antenna. Take periodic breaks during 
prolonged recharging. Although no direct cause and effect has been established, some patients have 
reported heating sensation, discomfort, blistering not caused by heating, skin irritation, or redness near 
the implanted neurostimulator during or after recharging.
Frequency of recha rging -per the patient programmer labeling subjects should check the battery level of 
their INS on a daily basis.  Due to the higher pulse density of HD stim ulation setting the recharging 
intervals may need to be more frequent. Daily activities may be disrupted based on the fact that 
subjects may need to recharge more frequently as a result of the programmed parameters used in this 
study.  Subjects should pay particular atte ntion to Charging Efficiency and Battery Charge Level 
indicators on the recharger. 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 51of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateCheck the neurostimulator battery charge level once a day or more frequently as needed. 
Keep the neurostimulator sufficiently charged to maintain therapy.  It can be charg ed at any 
time; you do not need to wait for a low battery message. 
During neurostimulator recharging, monitor the Charging Efficiency row and adjust the 
antenna to obtain as many solid black boxes as possible. If only two boxes are filled in (6 or 
more bo xes are empty) adjust the antenna to improve the signal strength between the 
neurostimulator and recharger. 
During recharging, ensure the neurostimulator Battery Charge Level is at least 25% before 
ending the charge session.  However, a full battery charg e is ideal.
10.1.5. Pregnancy Risks
Pregnant women are not able to take part in this study.  Female subjects must agree to not become 
pregnant during the study by using a medically acceptable method of birth control. If a subject become s
pregnant during this study, there may be risks to theunborn child that are not yet known.  The study 
doctor should be notified immediately if the patient think sthey are or have become pregnant.  The
stimulator will be turned “OFF” and the patient will be exited from the study.
10.1.6. Radiographic Imaging
As part of the study, subjects will be required to have fluoroscopic or X -ray images taken of their thoracic 
spine 1 time in addition to the imaging conducted to implant the leads .  This may be beyond what is 
standard of care .  The risk associated with these additional images has been considered and determined 
to be minimal since the total radiation dose will be approximately the same as one CT scan of the 
abdomen .   
10.2. Study Risk Control Measures 
The fol lowing will be done to mitigate risks associated with the implanted system :
Investigators who are experienced with spinal cord stimulation implantat ion techniques will 
be utilized
Instructions will be given to the study participants to ensure they can prop erly use the 
patient programmer and recharg er system
Subjects can turn off stimulation at any time during the study with the patient programmer 
or recharger
Periodic monit oring of the study participants
Labeling that contains precautions, warnings, and con traindications, as well as instructions 
on the use of the devices will be available and/or provided to the clinicians and subjects
10.3. Potential Benefits
Spinal cord stimulation may reduce low back or leg pain intensity, return the patient to a more fully 
functional status, and/or improve quality of life. Additionally, with stimulation delivered at comfort
threshold amplitudes, subjects may avoid uncomfortable or even intolerable stimulation sensations, 
such as painful paresthesia. During the study s ubjects will have increased interaction with physicians or 
medical staff compared to routine clinical care, which may provide some indirect health benefits.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 52of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateData from this study may have the anticipated benefit of helping Medtronic with the understanding of 
SCStherapy and assist ingwith the design of future studies and product improvements.  The information 
gathered from this study could also help clinicians optimize therapy for their patients.    
10.4. Risk-Benefit Rationale
Neurostimulation therapies, such as SCS, are used as an aid in the management of chronic, intractable 
pain that cannot be effectively managed with medications and/or other conservative treatments alone. 
Patients considered for neurostimulation th erapy have typically had pain of long duration and have 
failed multiple therapeutic paths. Findings from clinical studies documented in published literature 
suggest that T9/T10 has been a common location to target stimulation for chronic back and leg pain.
Medtronic has carefully designed and tested the RestoreSensor SureScan MRI and In tellis AdaptiveStim
Neurostimulation System sto ensure the safety and performance for the treatment of chronic, 
intractable pain . Medtronic has completed an extensive risk analysis to ensure the identification of 
potential hazards and subsequent mitigation of these hazards to eliminate them entirely or reduce them 
to an acceptable level. 
The risks associated with the surgical imp lantation of the device , device use, and device failures are the 
same those observe d for commercially available SCS devices. With an existing pre -market application
approval for the commercially available RestoreSensor SureScan MRI and Intellis AdaptiveStim
Neurostimulation System s, an established safety profile of probable benefit outweigh ing risk already 
exists for SCS Therapy for chronic back and/or leg pain. In most cases implantation of SCS is a reversible 
procedure and the system can be tur ned off or removed. Moreover, stimulation parameters are 
adjustable to minimize or reverse complications and maximize therapeutic effects. System output and 
programming parameters used with the proposed HD stimulation parameters are within the range of
thecommercially available RestoreSensor SureScan MRI and Intellis AdaptiveStim Neurostimulation 
System s.However, s ome subjects may not receive effective pain relief with the proposed HD stimulation 
parameters . HD stimulation non -responders willbe managed i n the same manner as commercial 
patient s, and their devices may be programmed to any combination of parameters chosen by their 
physician. The anticipated benefits of the clinical outcomes of SCS therapy per the study design 
outweigh the overall risk.
11. Adver se Event s and Device Deficiencies
11.1. Definitions/Classifications
Each adverse event is classified according to ISO 14155:2011 Where the definition indicates “device”, it 
refers to any device used in the study. See geography -specific addenda for applicable OUS information.
Term Definition
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 53of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAdverse Event (AE): 
(ISO 14155:2011 3.2)Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, 
users or other persons, whether or not related to the investigational medical 
device. 
NOTE 1: This definition includes events related to the investigational 
medical device or the comparator .
NOTE 2: This definition includes events related to the procedures 
involved.
NOTE 3: For users or other persons, this definition is restricted to 
events related to investigational medical devices.
Adverse Device Effect 
(ADE): 
(ISO 14155:2011 3.1)Adverse event related to the use of an investigational medical device.
NOTE 1: This definit ion includes adverse events resulting from 
insufficient or inadequate instructions for use, deployment, 
implantation, installation, or operation, or any malfunction of the 
investigational medical device.
NOTE 2: This definition includes any event resulting from use error 
or from intentional misuse of the investigational medical device.
Device Deficiency 
(DD):
(ISO 14155:2011 3.15)Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance .
NOTE : Device deficiencies include malfunctions, use errors, and 
inadequate labeling.
Malfunction: 
(ISO 14155:2011 3. 27)Failure of an investigational medical device to perform in accordance with its 
intended purpose when used in accordance with th e instruction s for use or 
(CIP) .
Use Error:
(ISO 14155:2011 3.43)Act or omission of an act that results in a different medical device response 
than intended by the manufacturer or expected by the user .
NOTE 1: Use error includes slips, lapses, and mistakes.
NOTE 2: An unexpected physiological response of the subject does 
not in itself constitute a use error . 
Term Seriousness
Serious Adverse 
Event (SAE):
(ISO 14155:2011 3.37)Adverse event that
a)led to death,
b)led to serious deterioration in the health of the subject, that either 
resulted in
1)a life -threatening illness or injury, or
2)a permanent impairment of a body structure or a body function, 
or
3)in-patient or prolonged hospitalization, or
4)medical or surgical intervention to prevent life -threatening 
illness or injury or permanent impairment to a body structure or 
a body function, 
c)led to foetal distress, foetal death or a congenital abnormality or 
birth defect.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 54of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateNOTE: Planned hospitalization for a pre -existing condition, or a 
procedure required by the CIP, without serious deterioration in 
health, is not cons idered a serious adverse event.
Serious Adverse 
Device Effect (SADE): 
(ISO 14155:2011 3.36)Adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event
Unanticipated Serious 
Adverse Device Effect 
(USADE):
(ISO 14155:2011 3.42)Serious adverse device effect which by its nature, incidence, severity or 
outcome has not been identified in the current version of the risk analysis 
report .
NOTE: Anticipated serious adverse device effect (ASADE) is an effect 
which by its nature, incidence, severity or outcome has been 
identified in the risk analysis report.
Term Relatedness
Device Related An adverse event that results from the presence or performance (intended 
or otherwise) of the Neuromodulation System
Therapy Related Event related to therapy delivery by device. Normally therapy -related events 
resolve when the device is turned off or reprogrammed. This category 
should not incl ude events that resulted from a malfunction of the device (i.e. 
hardware -related events).
Procedure Related An adverse event that occurs due to any procedure related to the 
implantation, surgical modification of the system or programming .
11.2. Foreseeable Adverse Events and Anticipated Adverse Device 
Effects
All anticipated adverse events and adverse device effects are the same as those foreseeable risks listed 
in Section 10.1 .
11.3. Recording of Adverse Events
In this study, only device -, therapy -and procedure -related adverse events (AEs) and device deficiencies 
that occur from enrollment through subject discontinuation from the study will be collected. Adverse 
event and device deficiency information will be reported to Medtronic on an adverse event or device 
deficiency eCRF, one for each AE and/or device deficiency . 
It is the responsibil ity of the investigator to identify the occurrence of device -, therapy -or procedure -
related adverse events and device deficiencies and to ensure all required information is accurately 
recorded on the eCRF. Refer to the applicable eCRF for the information to be reported for each adverse 
event and device deficiency.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 55of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateFor adverse events t hat require immediate reporting , initial reporting to Medtronic may be done by 
phone, or e -mail, or on the eCRF by completing as much information as is available. The adverse event
eCRF must be completed as soon as possible.
In case the investigator requires information from the sponsor in an emergency situation, the 
investigator can contact Medtronic using the contact details provided in the synopsis and Section 11.7 .
The clinical course of each adverse event must be followed until the adverse event is resolved, the 
subject is in a stable condition, or until the subject discontinues fr om the study . “Ongoing” adverse 
events and device deficiencies must be assessed at each study visit. The adverse event eCRF should be 
updated when there is a change to the information provided on the form ( e.g. change in intervention , 
outcome, relatedness, etc.).
At the last scheduled visit, the investigator will instruct the subject to provide an update on the status of 
any ongoing events and report any adverse event or issue with the device that they believe might be 
related to participation in the study .    
11.4. Recording of Device Deficiencies
Device deficiency information will be collected throughout the study and reported to Medtronic on a 
device event eCRF, one for each device deficiency.   The investigator must determine and document on 
the eCRF device de ficiencies that did not lead to an adverse event but could have led to a serious 
adverse device effect:
If either suitable action had not been taken
If intervention had not been made, or
If circumstances had been less fortunate
11.5. Adverse Event and Device De ficiency Reporting 
Requirements
only those Adverse Events (AEs) which are related to the following will be collected:
The implanted SCS system, accessories and surgical procedure s
SCS therapy
In addition, all device deficiencies reported during the study w ill be collected.
It is the responsibility of the Investigator to adhere to the adverse event reporting requirements as 
stated within the protocol or in the applicable country -specific addenda and to their IRB /ECreporting 
requirements. Unanticipated Serious Adverse Device Effects (USADE) must be reported to Medtronic 
within 24 hours of learning of the effect, and to the IRB /ECas required .  Medtronic is also responsible to 
report these events to participating inv estigators, IRBs /ECs , the FDA and or other regulatory agencies 
based on applicable local laws.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 56of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateUpon receipt of notification of adverse events and device deficiencies at Medtronic , a Medtronic study 
team member will review for completeness and ac curacy and when necessary, will request clarification 
and/or additional information from the investigator.   If Medtronic disagrees with the Investigator’s 
assessment of the adverse event, Medtronic study personnel will document the disagreement and 
report or ensure r eporting of both opinions to IRB/EC and regulatory agencies as required .  Medtronic 
will utilize the Medical Dictionary for Regulatory Activities (MedDRA) to assign a MedDRA term fo r each 
adverse event and device deficiency based on the information provide d by the investigator.
11.6. Non-Reportable Events
Events that are not reportable for this study are:
Lack of pain relief 
oPain symptoms will be collected as part of the efficacy measures
Sensation of stimulation (paresthesia)
oSensation of stimulation (e.g. t ingling, buzzing )will not be reported as this may 
occur as part of this therapy .  Exception: Sensation or stimulation events that are
uncomfortable to the subject (e.g. shocking, jolting) will be reported .
Adverse events unrelated to 
oImplanted SCS system, accessories orsurgical procedure
oSpinal cord stimulation therapy
Table 6provides a list of common expected surgical adverse events. An expected surgical event will not 
be considered reportable unless it worsens or is present outside the stated timeframe post -procedure.
Table 6: Expected Surgical Adverse Events and Durations
Event descriptionTime frame after the surgical 
procedure
Anesthesia -related nausea/vomiting 24 hours
Mild to moderate pain at surgical site 7 days
Low-grade fever (<100ºF or < 37.8ºC) 48 hours
Mild to moderate bruising / ecchymosis 7 days
Pocket site / incisional pain 14 days
Seroma 72 hours
Sleep problems (insomnia) 72 hours
11.7. Emergency Contact Details 
For emergency contact regarding an SADE /DD, contact the Clinical Study Manager immediately.   Refer 
to the country specific addenda for OUS information.
24-hour Medtronic contact information for reporting SADEs/DD: 
Email: rs. neuadverseeventreporting @medtronic.com 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 57of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplatePhone (US) : +1 (765) 505 -9036
11.8. Deaths
The investigator must notify Medtronic immediately and the IRB /EC, as required, after learning of a 
subject’s death, regardless of whether or not the death is related to the device system , therapy or
procedur e.  The investigator should also attempt to determine, as conclusively as possible, whether such 
deaths are related to the device system , therapy, or procedure . If the death is evaluated as device -, 
therapy -,orprocedure -related , and unanticipated, the event will be reported as a USADE by Medtronic 
to the appropriate regulatory authorities .
If it is determined that the cause of death was device -, therapy -, or procedure -related :
And an autopsy is conducted, a copy of the report should be provided to Medtronic.  
Medtronic requests that all device system components that were being used at the time of the 
death be returned to Medtronic for analysis pe r Section 7.8.  
Requested death certificates and/or source documentation if obtained should be redacted and 
sent to Medtronic.  
If the death occu rs at a location remote from the study site, it is the study site’s responsibility to 
make three attempt sto retrieve all pertinent information related to the subject’s death and 
submit the investigator’s death summary of the known events surrounding the d eath to 
Medtronic .
12. Data Review Committees 
This study will not use a Clinical Events Committee (CEC) , Adverse Events Advisory Committee (AEAC) or 
an independent Data Monitoring Committee (DMC) . Instead, all reported adverse events and device 
deficiencies will be reviewed by aMedtronic Medical Advisor to ensure consistent reporting .
13. Statistical Design and Methods
13.1. General Statistical Considerations
Data analysis will be performed by Medtronic -employed statisticians or designees. A validated statistical 
software package ( e.g., SAS version 9.4 or higher) will be used to analyze the study results.
The Statistical Analysis Plan (SAP) will be developed prior to data analysis and will include a 
comprehensive description of the statistical methods and reports to be included in the final study 
report. Any change to the data analysis methods described in the CIP will require an amendment only if 
it changes a principal feature of the CIP. Any other change to the data analysis methods described in the 
CIP, and the ju stification for making the change, will be described in the clinical study report .
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 58of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAll analyses will be pooled by neurostimulator model unless otherwise specified.  
PASS11 was used to calculate the sample size for the primary objective.
13.1.1. Analysis population s
There will be 4 population sets for the purposes of analysis in this study:
Enrolled Analysis Set: All consented subjects.
Trialed Analysis Set: All subjects who are implanted with trialing leads at T9/T10 and programmed at 
the Device Trial Day 0 Visit.
Implanted Analysis Set :All subjects who have a positive device trial with HD parameters at T9/T10 and 
areimplanted with a neurostimulation system . 
Treated Analysis Set: All subjects in the Implanted Analy sis Set whose devices are activated at the 
Device Activation Visit .
13.1.2. Handling of missing data 
The primary and secondary efficacy objective swill be evaluated for the Treated Analysis Set. For 
subjects in the Treated Analysis Set with missing outcome data, the missing outcome measure will be 
imputed using multiple imputations (MI ).  
 
 
 
Following imputation, the objectives will be evaluated using MI analysis methods.
Imputation for missing data may be implemented for the long -term additional measures analyses. 
13.1.3. Interim efficacy analyses
An interim analysis providing preliminary characterization of the secondary objectives will be performed 
in late 2018 with the intent of presenting the results in early 2019.   The details of the se analyses will be 
specified in the SAP.
Analyse s of the efficacy outcomes and safety assessment will be performed after 100 subjects have 
reached the 3 -Month Visit, as described in section 13.1.6 . The primary efficacy objective will not be 
evaluated. Theseanalys es will be specified in the SAP and are not intended to be used to modify th e 
study .  

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 59of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template13.1.4. Center pooling
All investigators in the proposed study will conduct the study according to a common protocol and 
utilize the same CRFs to collect study data. In addition, site study personnel training will be conducted 
prior to initiation of the study in each site and periodic monitoring will be conducted by Medtronic to 
ensure compliance with protocol requirements.
Data will be pooled across centers for all analyses. No single site will be allowed to implant more than 25 
subjects . This is intend ed to reduce the possibility that a site with atypical results will be overly 
influential in the study results based on pooled data. 
13.1.5. Multiple testing adjustment
The study has one primary objective that will be evaluated with statistical testing. The primary objective 
will be evaluated at an alpha level of 0.05 after all subjects in the Treated Analysis Set have completed 
the 3 -Month Visit. 
Therapy efficacy will be demonstrated by successfully passing the primary objective analysis. The 
secondary objective s are not alpha -controlled; they will be characterized but not evaluated with 
statistical testing.
13.1.6. Reports
 
 
 
 
13.2. Demographics
Demographics and baseline characteristics will be summarized for all enrolled subjects, as well as the 
subset of subjects in the Treated Analysis Set .
13.3. Primary Objective
13.3.1. Primary objective
To demonstrate a significant improvement in overall (low back and leg) pain intensity using HD 
stimulation starting at 90-200 µsecand 1000 Hz with lead placement spanning the T9/T10 disc space , 
as measured by the Visual Analog Scale (VAS), from Baseline to the 3 -Month Visit . 
13.3.2. Hypothesis
The mean change in overall pain in implanted subjects ( µc) from baseline to 3 months will be statistically 
significantly different from no change on the VAS scale 0 -100 mm:
H0: µc= 0
HA: µc≠ 0

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 60of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template13.3.3. Endpoint definition
The change in overall pain will be calculated for all subjects in the Treated Analysis Set as:
Baseline overall pain – 3-Month overall pain
The baseline and 3 -month overall pain scores will be collected on the Visual Analog Scale (VAS) at the 
Baseline and 3 -Month Visits, respectively. 
13.3.4. Study sample size justification
The Tests for One Mean in PASS11 was used to calculate the sample size. The assumptions of alpha = 
0.05, power = 0.9, null mean (Mean0) = 0, alternative mean (Mean1) = 20, standard deviation = 30, 
alternative hypothesis = Mean0 ≠Mean1, and Infinite population size, results in a sample size of 26 
subjects. However, a sample size of 100 subjects derived for the secondary objectives ( section 13.4 ) 
ensures over 99% power under those same assumptions .
Up to 215 subjects will be enrolled to ensure at least 100 subjects reach the 3 -month endpoint. 
13.3.5. Analysis methods
The two -sided, one sample t -test will be used to test the hypothesis of the primary objective. The main 
analysis will include all subjects in the Treated Analysis Set . In addition to the hypothesis test, the two-
sided 95% confidence interval for the averag e change in overall pain will be calculated and reported. 
13.3.6. Handling of missing data
The primary analysis for this efficacy objective will be evaluated for all subjects in the Treated Analysis 
Set. The method for handling missing data for the primary endpoi nt is described in section 13.1.2.
13.3.7. Sensitivity analyses 
Sensitivity analyses will be conducted for the primary efficacy objective using the methods described 
below:
Completers analysis: 
oOnly subjects in the Treated Analysis Set with complete paired data at the Baseline and 
3-Month Visits will be included in the analysis.
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 61of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
13.4. Secondary Objective s
13.4.1. Secondary objective 1: Overall pain responder rate
To characterize the overall (low back and leg) pain efficacy responder rate, as measured by the VAS, 
from Baseline to the 3 -Month Visit, with a confidence interval within ±10%.
Endpoint definition
The responder rate will be calculated as the proportion of subjects in the Treated Analysis Set who 
demonstrate at least a 50% improvement in overall pain from baseline to 3 months. For each subject, 
percentage improvement will be calculated as:
(Baseline overall pain – 3-M onth overall pain) x 100
Baseline overall pain
The baseline and 3 -month overall pain scores will be collected on the VAS at the Baseline and 3 -Month 
Visits, respectively. Subjects who report at least a 50% improvement in overall pain will be considered 
responders.
Study sample size justification
Calculations were performed using PASS11, Confidence Intervals for One Proportion, with Confidence 
Level = 0.95, P = 0.5, Confidence Interval Formula = Score (Wilson), Interval Type = Two -Sided. Table 7
shows the 95% confidence interval for a 50% responder rate for 50 -100 subjects. A sample size of 100 
subjects provides a 95% confidence interval within 9.6% of the responder rate estimate, if the observed 
responder rate is 50%. The confidence interval is the widest with a responder rate of 50%; a lower or 
higher responder rate will have a narrower confidence interval.
Table 7. 95% Confide nce Interval (CI) for Responder Rate = 50%
N Lower Limit Upper Limit CI Width +/-Range
50 36.6% 63.4% 26.7% 13.4%
60 37.7% 62.3% 24.5% 12.3%
70 38.6% 61.4% 22.8% 11.4%
80 39.3% 60.7% 21.4% 10.7%
90 39.9% 60.1% 20.2% 10.1%
100 40.4% 59.6% 19.2% 9.6%

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 62of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplateAnalysis methods
The responder rate as defined above will be calculated for subjects in the Treated Analysis Set.  The 
score (Wilson) method will be used to calculate the 95% confidence interval of the responder rate. In 
this analysis, missing data will be imputed as described above in section 13.3.6 . Sensitivity analyses will 
be performed as described in section 13.4.4 .
13.4.2. Secondary objective 2: Low back pain responder rate
To characterize the low back pain efficacy responder rate, as measured by the VAS, from Baseline to the 
3-Month Visit, with a confidence interval within ±10%.
Endpoint definition
The responder rate will be calculated as the proportion of subjects in the Treated Analysis Set who 
demonstrate at least a 50% improvement in low back pain from baseline to 3 months. For each subject, 
percentage improvement will be calculated as:
(Baseline low back pain –3-Month low back pain) x 100
Baseline low back pain
The baseline and 3 -month low back pain scores will be collected on the VAS at the Baseline and 3 -Month 
Visits, respectively. Subjects who report at least a 50% i mprovement in low back pain will be considered 
responders. 
Study sample size justification
Calculations were performed using PASS11, Confidence Intervals for One Proportion, with Confidence 
Level = 0.95, P = 0.5, Confidence Interval Formula = Score (Wilso n), Interval Type = Two -Sided. Table 8
shows the 95% confidence interval for a 50% responder rate for 50 -100 subjects. A sample size of 100 
subjects provides a 95% confidence interval within 9.6% of the responder rate estimate, if the observed 
responder rate is 50%. The confidence interval is the widest with a responder rate of 50%; a lower or 
higher responder rate will have a narrower confi dence interval.
Table 8. 95% Confidence Interval (CI) for Responder Rate = 50%
N Lower Limit Upper Limit CI Width +/-Range
50 36.6% 63.4% 26.7% 13.4%
60 37.7% 62.3% 24.5% 12.3%
70 38.6% 61.4% 22.8% 11.4%
80 39.3% 60.7% 21.4% 10.7%
90 39.9% 60.1% 20.2% 10.1%
100 40.4% 59.6% 19.2% 9.6%
Analysis methods
The responder rate as defined above will be calculated for subjects in the Treated Analysis Set.  The 
score (Wilson) method will be used to calculate the 95% confidence interval of the responder rate. In 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 63of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatethis analysis, missing data will be imputed as descr ibed above in section 13.1.2 . Sensitivity analyses will 
be performed as described in section 13.4.4 . 
13.4.3. Secondary objective 3: Leg pain responder rate
To characterize the leg pain efficacy responder rate, as measured by the VAS, from Baseline to the 3 -
Month Visit, with a confidence interval within ±10%.
Endpoi nt definition
The responder rate will be calculated as the proportion of subjects in the Treated Analysis Set who 
demonstrate at least a 50% improvement in leg pain from baseline to 3 months. For each subject, 
percentage improvement will be calculated as:
(Baseline legpain –3-Month leg pain) x 100
Baseline leg pain
The baseline and 3 -month leg pain scores will be collected on the VAS at the Baseline and 3 -Month 
Visits, respectively. Subjects who report at least a 50% improvement in leg pain will be considered 
responders. 
Study sample size justification
Calculations were performed using PASS11, Confidence Intervals for One Proportion, with Confidence 
Level = 0.95, P = 0.5, Confidence Interval Formula = Score (Wilson), Interval Type = Two -Sided. Table 9
shows the 95% confidence interval for a 50% responder rate for 50 -100 subjects. A sample size o f 100 
subjects provides a 95% confidence interval within 9.6% of the responder rate estimate, if the observed 
responder rate is 50%. The confidence interval is the widest with a responder rate of 50%; a lower or 
higher responder rate will have a narrower c onfidence interval.
Table 9. 95% Confidence Interval (CI) for Responder Rate = 50%
N Lower Limit Upper Limit CI Width +/-Range
50 36.6% 63.4% 26.7% 13.4%
60 37.7% 62.3% 24.5% 12.3%
70 38.6% 61.4% 22.8% 11.4%
80 39.3% 60.7% 21.4% 10.7%
90 39.9% 60.1% 20.2% 10.1%
100 40.4% 59.6% 19.2% 9.6%
Analysis methods
The responder rate as defined above will be calculated for subjects in the Treated Analysis Set.  The 
score (Wilson) method will be used to calculate the 95% confidence interval of the responder rate. In 
this analysis, missing data will be imputed as descr ibed above in section 13.1.2 . Sensitivity analyses will 
be performed as described in section 13.4.4 .  
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 64of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template13.4.4. Sensitivity analyses for the se condary objective s
Sensitivity analyses will be conducted for the secondary efficacy objectives using the methods described 
below:
Completers analysis: 
oOnly subjects in the Treated Analysis Set with complete paired data at the Baseline and 
3-Month Visits will be included in the analysis.
 
 
 
 
 
 
13.5. Additional Measures
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 65of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
Summary statistics will be presented for continuous measures (N, means, medians, standard deviations, 
minimums and maximums) and categorical measures (N, percent, freque ncy distributions) with 95% 
confidence intervals as appropriate. Missing data imputation may be performed on long -term outcome 
measures. No multiplicity adjustment will be performed for characterizations of the additional study 
measures. 
13.6. Safety Assessment
All device -, therapy -,or procedure -related adverse events and device deficiencies from enrollment to 
study exit will be summarized. Adverse events and device deficiencies will be coded and summarized 
using the Medical Dictionary for Regulatory Affairs (MedDRA). Summaries will be presented as the 
number of events, the number of subjects who experienced the event, and the percent of subj ects who 
experienced the event. Adverse events and device deficiencies will be summarized by study phase ( e.g., 
Baseline, Trialing, Implant), with the appropriate number of corresponding subjects as the denominator 
within each study phase.
14. Ethics
14.1. Stateme nts of Compliance 
This study will be conducted in compliance with this CIP and good clinical practice according to the 
International Conference on Harmonization (ICH GCP E6), the ethical principles that originate from the 
Declaration of Helsinki and in th e United States (US) , the Code of Federal Regulations (CFR) on Electronic 
records (21 CFR§11), Protection of human subjects (21 CFR§50 ), Institutional review boards (21 CFR 
§56), Medical Device Reporting (21CFR§803),  and applicable local regulatory requir ements and laws in 
the states and geographies in which the study will be conducted. Refer to the geography -specific 
addendum for more information.  This study will be posted on http://www. ClinicalTrials.gov as part of 
Medtronic’s commitment to full disclos ure for ongoing studies that meet the requirements for public 
posting .
The principles of the Declaration of Helsinki have been implemented through the patient informed 
consent (IC) process, IRB/ECapproval, study training, clinical trial registration, preclinical testing, risk -
benefit assessment and publication policy.

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 66of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan TemplatePrior to enrolling subjects in this study, each study site’s IRB /ECwill be required to approve the current 
CIP or CIP amendments , the subject ICF, including any other written information to be provided to the 
subjects and, if applicable, any materials used to recruit subjects. IRB /ECapproval letters must contain 
sufficient information to identify the version and/or date of the docum ents that were approved, or the 
information must be retrievable from the corresponding submission letter. Sites must also receive 
written approval from Medtronic prior to initiating subject enrollments. Any additional requirements
imposed by the IRB/EC or regulatory authority will be followed and documented, if appropriate.
Investigators will be required to sign a Statement of Investigator Commitment form stating their intent 
to adhere to applicable regulations.
Thesponsor shall avoid improper influence on , or inducement of, the subject, monitor, any 
investigator(s) or other parties participating in, or contributing to, the clinical investigation. All 
investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other 
inves tigator(s) or other parties participating in or contributing to the clinical investigation.
15. Study Administration
15.1. Monitoring 
Medtronic is responsible for ensuring the proper conduct of this study in terms of adherence to 
applicable regulations, protocol co mpliance, and the validity and accuracy of the study data entered on 
eCRFs.  As such, investigational sites will be monitored to ensure the safety and well -being of study 
subjects is preserved, and to ensure site compliance with the study protocol, applica ble regulations, and 
the study data is accurate and complete. 
Monitoring and monitoring oversight will be provided by Medtronic personnel or by representatives of 
Medtronic (i.e. contractors and other designe es) who will support the study investigation in cluding site 
qualification, site initiation, interim monitoring and study closure visits .
Contact information for the study monitoring:
Core Clinical Solutions Monitor Group
8200 Coral Sea Street, N.E., MVS33
Mounds View, MN 55112
The principal investigato r and study staff will provide the Medtronic monitors with complete and direct 
access to source data (e .g., paper and electronic hospital/clinical charts, appointment books, laboratory 
records) that support the data on the eCRFs ,as well as other documenta tion supporting the conduct of 
the study.  Monitors will perform source data verification , routine reviews of study -related regulatory 
documents , including product accountability during scheduled monitoring visits ,and work to secure 
compliance should any deficiencies be observed. The monitoring plan is maintained as a separate 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 67of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatedocument on file at Medtronic and contains the procedure and strategy for frequency of monitoring 
visits and extent source data verification to be performed for this study.
The principal investigator must make every effort to meet with the monitor during each monitoring visit.
15.2. Medtronic Representative Role
Medtronic representatives who are qualified and trained on the protocol may participate in the conduct 
of the study under the direct supervision of the principal investigator as described below.  The principal 
investigator or other study site personnel designated on the delegation of authority form must collect all 
required data, record the s tudy activities, and be responsive to the subject’s needs during an activity 
performed by a Medtronic representative.
Medtronic representatives may provide technical support to the investigator and other health care 
personnel as needed during study visits.   This support may include the training of site personnel on use 
of the Medtronic equipment or the protocol -related procedures and data collection.
In addition, Medtronic personnel may perform certain activities to ensure study quality.  These activities 
may include:
Provide technical support during device trial, implant and follow -up visits.  
Perform device programming, device interrogation, device download while under the 
direction of the investigator.
Discuss any issues with programming or subject compliance with the principal investigator 
or site personnel.
Clarify and/or troubleshoot device behavior, operation, or diagnostic output as requested by 
the Principal Investigator or other health care professional
Perform device interrogation, printing or uploading of device information while under the 
direction of the investigator or study site personnel delegated responsibility for device 
programming and assist with the collection of study data from equipment and upload into 
the NPU database
Medtronic personnel may not perform the following:
Practice medicine, provide medical diagnoses or make decisions related to subject 
treatment/care
Discuss a subject’s condition or medical treatment with the subject or a member of the 
subject’s family
Express opinio ns about the product/feature under study
Assist the subject by direct physical contact except as required by the specific protocol -
related task to be conducted
Provide the subject with any form/questionnaires related to the products under 
investigation
Enter data on eCRFs, with the exception of Medtronic Use Only fields /forms
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 68of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template15.3. Data Management
This study will use the Oracle Clinical Remote Data Capture (RDC) system, which allows the study centers 
to enter data directly onthe eCRF with in the sponsor’s databas e over a secure internet connection. This 
system isa21CFR§11 Part E compliant, fully -validated system that controls user access, ensures data 
integrity, and maintains an audit trail of entries, changes or corrections made to the eCRFs . User access 
will be granted by Medtronic to each applicable individual at a site based upon his or her delegation of 
authority for the study and only upon completion of the required training. The Investigator and 
applicable study site personnel will be given access to the electronic eCRF system; user IDs and 
passwords may not be shared.
The principal investigator is responsible for the overall quality (completeness , accuracy and timeliness ) 
of the data entered on the eCRFs and the data in all other requir ed reports.  The principal investigator or 
sub-investigator (physician only) must review all data for accuracy and provide his/her approval of the 
eCRF and sign each form with an electronic signature . Data reported on the eCRFs, must be derived 
from and co nsistent with source documents , unless otherwise stated in this section or the study 
monitoring plan . If discrepancies in source are identified ( e.g., during monitoring), these need to be 
corrected or justified with a documented rationale, signed and dated by the principal investigator, or 
authorized delegate, to be maintained as a part of the subject’s records .If a person only authorized to 
complete eCRFs makes changes to an already signed eCRF, the system will require the principal 
investigator, or autho rized delegate, to re -sign the eCRF.
The eCRF may be considered source for the following data collection elements :
Investigator assessment of adverse event relatedness and seriousness
Detail spertaining to and reason for p rotocol deviation
Even when the CRF may be considered as source (as noted above) , an alternative method of source 
documentation is always strongly encouraged. 
Medtronic personnel will perform routine edit and consistency checks, in -house and during monitoring 
visits, for items such as m issing data or inconsistent data.  Identified data inconsistencies will be 
resolved by use of data queries; investigators and site personnel will review data queries and respond to 
them in a timely manner. The resolved discrepancy will become a part of the eCRF record for the 
subject. At the end of the study, the data will be frozen (locked) and will be retained indefinitely by 
Medtronic.
15.4. Direct Access to Source Data/Documents 
Source documentation is defined as the original documents, data and records and m ay include all
clinical records, hospital records, laboratory notes, surgery reports, autopsy reports, and other 
documents, electronic or paper, that contain original information to support study data collections or AE
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 69of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatereporting. The Principal Investigator is responsible for ensuring source documentation is complete, 
legible and accurate; and entries are made in a timely manner by appropriately delegated study staff . 
The Principal Investigator and site personnel will provide the Medtronic monitor(s) with direct access to 
source documentation or certified copies that support sthe data on the eCRFs as well as other 
documentation supporting the conduct of the study.  
Medtronic or third -party auditors representing Medtronic may perform clinical site audits to verify the 
performance of the monitoring process , study conduct, and to ensure compliance with applicable 
regulations. Representatives f rom regulatory bodies such as the FDA may also perform site inspections 
related to this clinical study.  The Principal Investigator, site personnel, and institution will provide 
monitors, auditors , and FDA with direct access to source d ocumentation and all study -related 
documentation. 
Medtronic will investigate suspected cases of fraud or misconduct as appropria te.
15.5. Confidentiality
All records and other information about subjects participating in this clinical study will be treated as 
confidential. Subject confidentiality will be maintained throughout the clinical study to the extent 
permitted by law. For this purpose, a unique study -specific subject identification code (study -site -
subject number) will be assigned and used to allow identification of all data reported to Medtronic for 
each subject. Subject confidentiality is assured through the use o f the study -specific subject 
identification numbers, use of initials only, and the de -identifying of subjects’ records obtained by or 
provided to the Sponsor. 
For purposes of monitoring this study, access to clinic and hospital records must be available t o 
Medtronic, representatives of Medtronic (i.e. contractors and other designees) , the FDA and other 
regulatory agencies.  Study data may be made available to third parties ( e.g., in the case of an audit or 
inspection performed by regulatory authorities), p rovided the data are treated confidentially and the 
subject’s privacy is guaranteed. The identity of a subject will never be disclosed in the event study data 
are published. Only anonymized data will be analyzed and published.
In addition to the review of records at the center, release of de -identified records to Medtronic m ay be 
necessary . The investigational site personnel must make every effort to de-identify and label source 
documentation with the subject’s study -specific identification number prior to submission of the records 
to Medtronic.
Health Insurance Portability and Accountability Act (HIPAA) language will be required to be included at 
every center in the US . HIPAA language may be included within the ICF according to the center’s policy.   
Data pr ivacy language will be included as required by geographic regulations and described in the 
geography -specific addenda.
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 70of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template15.6. Liability
The compensation and covered liability associated with this study conduct will be documented in a 
separate financial agreement signed by Medtronic, the principal investigator, and or the management of 
study site/institution.
15.7. CIP Amendments
Protocol amendments may be initiated by Medtronic to address changes to the scope or conduct of the 
study. Protocol amendments , and associated documents, must be approved by Medtronic and
submitted to the reviewing IRBs /ECs for approval prior to implementation except when necessary to 
eliminate an immediate/or apparent immediate hazard to participating subjects .
15.8. Record Retention
15.8.1. Investigator Records
Documentation for this study will be produced and maintained to ensure that a complete history of the 
study exists.  Documents created for this study, including all versions of original documents, will be 
identifiable and appropriately stored to assure control and traceability of data related to this study.
The principal investigator is responsible for the ensuring that all essential study documentation is 
retained and accessible for a minimum of 2 years (or longer as local law or facility administratio n 
requires) after the investigation is terminated or completed .  The retention period may be longer if 
required by Medtronic ,local or global regulatory requirements. Medtronic will be responsible for 
notifying sites of extensions to the 2 -year minimum rec ord retention requirements.  Medtronic must be 
notified in writing by site personnel of any transfer of study documentation.  The principal investigator 
will ensure that essential study documents are not destroyed until written permission has been 
obtained from Medtronic or if allowed per contract .  
At a minimum ,the investigator is responsible for the preparation, review, submission to Medtronic and 
retention of all signed and dated case report forms, reportable adverse events, device deficiencies, 
subjec t deaths, deviations from the CIP. In addition, investigators are also responsible for maintaining all 
correspondence with another investigator, an IRB /EC, the sponsor, a monitor, FDA or other local 
regulatory authority , related to this study (including approval documentation), r ecords of each subject’s 
case history and exposure to the device (including signed and dated informed consent forms & HIPAA or 
other data privacy authorizations as required by local authority ), final report, and all other study -related 
documentation.
15.8.2. Investigator Reports
The principal investigator is responsible for the preparation (review and signature) and submission to 
the sponsor of all case report forms, adverse events, device deficiencies, deaths, and any deviations 
from the Clinical Investigation Plan. If any action is taken by an IRB/ECwith respect to this clinical study, 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 71of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatecopies of all pertinent documentation must be forwarded to Medtronic in a timely manner. Reports are 
subject to inspection and to the retention requiremen ts as described above for investigator records. 
Investigator reporting requirements for termination or suspension are listed in Section 15.10 . The 
investigator shall prepare and submit in a complete, accurate and timely manner the reports listed in 
this section.
15.9. Publication and Use Information
Medtronic may publish the results from the Vectors Post Market study .These publication activities may 
inclu de abstracts, presentations /posters to scientific meetings, and manuscripts.   Specific requirements 
regarding publication of study data will be provided in the publication plan. All proposed publications 
must be reviewed and approved by Medtronic prior to publication.  If required by a publisher, the 
principal investigator agrees to obtain all necessary authorizations from study subjects prior to 
submitting study -related informati on for publication .
Authorship Selection
Principal investigators who enroll subjects and compl ywith the protocol will be eligible to act as 
publication authors and may be asked to write or contribute to the writing of abstracts and manuscripts . 
Final auth orship will be based on the Ethical Considerations in the Conduct and Reporting of Research as 
defined by the International Committee of Medical Journal Editors (http://www.icmje.org). All 4of the 
following criteria must be met for authorship: 
1.Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of data
2.Drafting the article or revising it critically for important intellectual content
3.Final approval of the version to be published
4.Agreement to b e accountable for all aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are appropriately investigated and 
resolved
Lead authorship will be given to the principal investigator who meets the criteri a listed above and has 
the highest number of evaluable subjects. If there is a tie for lead authorship, the authors will be listed 
in alphabetical order. Medtronic personnel who meet the criteria for authorship will have the right to be 
listed as an author . Other significant contributors to the study who do not meet the criteria for 
authorship will be listed in the acknowledgement section of the publication.
15.10. Suspension or Early Termination
Early Termination is the closure of a clinical study that occurs pr ior to meeting defined endpoints. This is 
possible for the whole study or a single center. Suspension is a temporary postponement of study 
activities related to enrollment. This is possible for the whole study or a single center. Medtronic 
reserves the rig ht to suspend or terminate the study or an individual study site at any time .  In the event 
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 72of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Templatethat the study is terminated, the s ubject ’sdevices will be programmed as per the Investigator’s 
discretion and once exited from the study, subjects will be managed by their physician.
15.10.1. Study -wide termination or suspension
Medtronic reserves the right to suspend or terminate the study at any time.  R easons may include, but 
are not limited to , the following :
Insufficient enrollment to complete the study within the exp ected timeframe
Identification of adverse events or safety issues with the product or system that may impact 
the safety or welfare of study subjects
Product performance/product supply issues
15.10.2. Investigator/center termination or suspension
Medtronic reserves the right to suspend or terminate the study at an individual site.  Reasons may 
include, but are not limited to, the following:
Noncompliance with the protocol 
IRB/ECapproval lapse/expiration
Serious or repeated deviations at the site
Failure to implemen t required corrective and preventive actions
Insufficient enrollment to complete the study within the expected timeframe
Loss of appropriately trained site personnel
Investigator request (e.g. no longer able to support the study)
Investigators are required to notify the IRB /ECof study suspension/termination.  Subjects will be 
notified by the investigator of suspension/termination due to unacceptable risk or of termination due to 
any other cause .
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 73of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template16. References
1. Shealy CN, Mortimer JT, Reswick JB. Electrical inhibition of pain by stimulation of the dorsal 
columns: preliminary clinical report. Anesth Analg . 1967;46(4):489 -491. 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Citation&list
_uids=4952225 .
2. Miller JP, Eldabe S, Buchser E, Johanek LM, Guan Y, Linderoth B. Parameters of Spinal Cord 
Stimulation and Their Role in Electrical Charge Delivery: A Review. Neuromodulation . 
2016;19(4):373 -384. doi: 10.1 111/ner.12438 .
3. De Ridder D, Vanneste S, Plazier M, van der Loo E, Menovsky T. Burst spinal cord stimulation: 
toward paresthesia -free pain suppression. Neurosurgery . 2010;66(5):986 -990. 
doi:10.1227/01.NEU.0000368153.44883.B3 .
4. Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown 
LL, Yearwood TL, Bundschu R, Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10 -kHz High -
frequency Therapy (HF10 Ther apy) Is Superior to Traditional Low -frequency Spinal Cord 
Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA -RCT Randomized 
Controlled Trial. Anesthesiology . 2015;123(4):851 -860. doi: 10.1097/ALN.0000000000000774 .
5. Barolat G, Massaro F, He J, Zeme S, Ketcik B. Mapping of sensory responses to epidural 
stimulation of the intraspinal neural structures in man. J Neurosurg . 1993;78(2):233 -239. 
doi:10.3171/jns.1993.78.2.0233 .
6. Barolat G, Oakley JC, Law JD, North RB, Ketcik B, Sharan A. Epidural spinal cord stimulation with 
a multiple electrode paddle lead is effective in treating intractable low back pain. 
Neuromodul ation . 2001;4(2):59 -66. doi: 10.1046/j.1525 -1403.2001.00059.x .
7. Grider JS, Manchikanti L, Carayannopoulos A, Sharma ML, Balog CC, Harned ME, Grami V, Justiz 
R, Nouri KH, Hayek SM, Valle jo R, Christo PJ. Effectiveness of Spinal Cord Stimulation in Chronic 
Spinal Pain: A Systematic Review. Pain Physician . 2016;19(1):E33 -E54. 
http://libcontent.medtronic.com:2133/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Cit
ation&list_uids=26752493 Free Article .
8. Van J. -P. B and BL. “The failed back surgery syndrome”: Definition and therapeutic algorithms -
An upda te. European Journal of Pain Supplements . 2010;4(4):273 -286. doi: DOI: 
10.1016/j.eujps.2010.09.006 .
9. North RB, Kidd DH, Olin J, Sieracki JM, Farrokhi F, Petrucci L, Cutchis PN. Spinal cor d stimulation 
for axial low back pain: a prospective, controlled trial comparing dual with single percutaneous 
electrodes. Spine (Phila Pa 1976) . 2005;30(12):1412 -1418. doi: 00007632 -2005 06150 -00012 [pii] .
10. North RB, Kidd DH, Olin J, Sieracki JN, Petrucci L. Spinal cord stimulation for axial low back pain: 
a prospective controlled trial comparing 16 -contact insulated electrodes with 4 -contact 
percutaneous electrodes. Neuromodulation . 2006;9(1):56 -67. doi: 10.1111/j.1525 -
1403.2006.00043.x .
11. Sharan A, Cameron T, Barolat G. Evolving patterns of spinal cord stimulation in patients 
implanted for intractable low back and leg pain. Neuromodulation . 2002;5(3):167 -179. 
doi:10.1046/j.1525 -1403.2002.02027.x .
Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 74of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template12. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective 
outcome measures. J Manipulative Physiol Ther . 2004;27(1):26 -35. 
doi:10.1016/j.jmpt.2003.11.003 .
13. EuroQol--a new facility for the measurement of health -related quality of life. Health Policy . 
1990;16(3):199 -208. http://libcontent.medtronic.com:2133/pubmed/10109801 .
14. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back pain disability questionnaire. 
Physiotherapy. 1980;66(8):271 -273. http://libcontent.medtronic.com:2133/pubmed/6450426 .
17. Appendice s 
17.1. Appendix AAdditional Information for Sites 
Detail ed sponsor contact information not outlined in the Clinical Investigational Plan will be provided 
under a separate cover.
17.2. Appendix B: Institutional Review Board s
At the time of the completion of the Ve ctors Post Market Clinical Investigation Plan, site selection is not 
yet complete. Therefore, a complete list of participating IRB/EC names, locations, and the Chairperson(s) 
will be distributed under a separate cover when available.
17.3. Appendix C: Participating Investigators and Institutions
At the time of completion of the Vectors Post Market Clinical Investigation Plan, site selection is not yet 
complete. Therefore, a complete list of names, addresses, and professional positions of the clinical 
investigators and institutions will be distributed under a separate cover when available.
18. Version History
Version Summary of Changes Author(s)/Title
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 75of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 76of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 77of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template4.0  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 78of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7053 Version 4.0    08May 2018 Page 79of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 

Vectors Post Market Clinical Investigation Plan
#MDT1 7 0 53 Version 4.0    08May 2018 Page 80of 80
Medtronic Confidential
056-F275, v3.0 Clinical Investigation Plan Template 
 
 
 
 
 
 
